<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prostanoids for critical limb ischaemia - Vietto, V - 2018 | Cochrane Library</title> <meta content="Prostanoids for critical limb ischaemia - Vietto, V - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006544.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prostanoids for critical limb ischaemia - Vietto, V - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006544.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006544.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prostanoids for critical limb ischaemia" name="citation_title"/> <meta content="Valeria Vietto" name="citation_author"/> <meta content="valeria.vietto@hospitalitaliano.org.ar" name="citation_author_email"/> <meta content="Juan VA Franco" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano" name="citation_author_institution"/> <meta content="Victoria Saenz" name="citation_author"/> <meta content="Unidad Asistencial Dr. César Milstein" name="citation_author_institution"/> <meta content="Denise Cytryn" name="citation_author"/> <meta content="Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Jose Chas" name="citation_author"/> <meta content="Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Agustín Ciapponi" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006544.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006544.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006544.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006544.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alprostadil [therapeutic use]; Amputation, Surgical [statistics &amp; numerical data]; Epoprostenol [therapeutic use]; Iloprost [therapeutic use]; Ischemia [*drug therapy, mortality]; Leg [*blood supply, surgery]; Leg Ulcer [drug therapy]; Nafronyl [therapeutic use]; Nicotinic Acids [therapeutic use]; Pentoxifylline [therapeutic use]; Peripheral Vascular Diseases [*drug therapy]; Prostaglandins [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Vasodilator Agents [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006544.pub3&amp;doi=10.1002/14651858.CD006544.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006544\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006544\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006544.pub3",title:"Prostanoids for critical limb ischaemia",firstPublishedDate:"Jan 10, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006544.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006544.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006544.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006544.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006544.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006544.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006544.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006544.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006544.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006544.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3987 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006544.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0160"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-sec-0151"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/appendices#CD006544-sec-0165"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/table_n/CD006544StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/table_n/CD006544StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prostanoids for critical limb ischaemia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#CD006544-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Valeria Vietto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#CD006544-cr-0003">Juan VA Franco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#CD006544-cr-0004">Victoria Saenz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#CD006544-cr-0005">Denise Cytryn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#CD006544-cr-0006">Jose Chas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information#CD006544-cr-0007">Agustín Ciapponi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information/en#CD006544-sec-0171">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006544.pub3">https://doi.org/10.1002/14651858.CD006544.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006544-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006544-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006544-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006544-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006544-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006544-abs-0001" lang="en"> <section id="CD006544-sec-0001"> <h3 class="title" id="CD006544-sec-0001">Background</h3> <p>Peripheral arterial occlusive disease (PAOD) is a common cause of morbidity and mortality due to cardiovascular disease in the general population. Although numerous treatments have been adopted for patients at different disease stages, no option other than amputation is available for patients presenting with critical limb ischaemia (CLI) unsuitable for rescue or reconstructive intervention. In this regard, prostanoids have been proposed as a therapeutic alternative, with the aim of increasing blood supply to the limb with occluded arteries through their vasodilatory, antithrombotic, and anti‐inflammatory effects. This is an update of a review first published in 2010. </p> </section> <section id="CD006544-sec-0002"> <h3 class="title" id="CD006544-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of prostanoids in patients with CLI unsuitable for rescue or reconstructive intervention. </p> </section> <section id="CD006544-sec-0003"> <h3 class="title" id="CD006544-sec-0003">Search methods</h3> <p>For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (January 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1). In addition, we searched trials registries (January 2017) and contacted pharmaceutical manufacturers, in our efforts to identify unpublished data and ongoing trials. </p> </section> <section id="CD006544-sec-0004"> <h3 class="title" id="CD006544-sec-0004">Selection criteria</h3> <p>Randomised controlled trials describing the efficacy and safety of prostanoids compared with placebo or other pharmacological control treatments for patients presenting with CLI without chance of rescue or reconstructive intervention. </p> </section> <section id="CD006544-sec-0005"> <h3 class="title" id="CD006544-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, assessed trials for eligibility and methodological quality, and extracted data. We resolved disagreements by consensus or by consultation with a third review author. </p> </section> <section id="CD006544-sec-0006"> <h3 class="title" id="CD006544-sec-0006">Main results</h3> <p>For this update, 15 additional studies fulfilled selection criteria. We included in this review 33 randomised controlled trials with 4477 participants; 21 compared different prostanoids versus placebo, seven compared prostanoids versus other agents, and five conducted head‐to‐head comparisons using two different prostanoids. </p> <p>We found low‐quality evidence that suggests no clear difference in the incidence of cardiovascular mortality between patients receiving prostanoids and those given placebo (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.41 to 1.58). We found high‐quality evidence showing that prostanoids have no effect on the incidence of total amputations when compared with placebo (RR 0.97, 95% CI 0.86 to 1.09). Adverse events were more frequent with prostanoids than with placebo (RR 2.11, 95% CI 1.79 to 2.50; moderate‐quality evidence). The most commonly reported adverse events were headache, nausea, vomiting, diarrhoea, flushing, and hypotension. We found moderate‐quality evidence showing that prostanoids reduced rest‐pain (RR 1.30, 95% CI 1.06 to 1.59) and promoted ulcer healing (RR 1.24, 95% CI 1.04 to 1.48) when compared with placebo, although these small beneficial effects were diluted when we performed a sensitivity analysis that excluded studies at high risk of bias. Additionally, we found evidence of low to very low quality suggesting the effects of prostanoids versus other active agents or versus other prostanoids because studies conducting these comparisons were few and we judged them to be at high risk of bias. None of the included studies assessed quality of life. </p> </section> <section id="CD006544-sec-0007"> <h3 class="title" id="CD006544-sec-0007">Authors' conclusions</h3> <p>We found high‐quality evidence showing that prostanoids have no effect on the incidence of total amputations when compared against placebo. Moderate‐quality evidence showed small beneficial effects of prostanoids for rest‐pain relief and ulcer healing when compared with placebo. Additionally, moderate‐quality evidence showed a greater incidence of adverse effects with the use of prostanoids, and low‐quality evidence suggests that prostanoids have no effect on cardiovascular mortality when compared with placebo. None of the included studies reported quality of life measurements. The balance between benefits and harms associated with use of prostanoids in patients with critical limb ischaemia with no chance of reconstructive intervention is uncertain; therefore careful assessment of therapeutic alternatives should be considered. Main reasons for downgrading the quality of evidence were high risk of attrition bias and imprecision of effect estimates. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006544-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006544-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006544-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006544-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006544-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006544-abs-0004">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006544-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006544-abs-0002" lang="en"> <h3>Prostanoids for people with severely blocked arteries of the leg</h3> <p><b>Background</b> </p> <p>People with severely blocked arteries of the leg suffer from pain, ulcers (areas showing loss of skin that do not heal easily), or gangrene (areas showing dead tissues resulting from loss of blood supply). This condition is usually associated with several risk factors, such as diabetes, smoking, high cholesterol, high blood pressure, obesity, and unhealthy lifestyle. The main treatments for people with this condition are surgical procedures performed to unblock the arteries. However, in some situations, surgical unblocking is not possible and amputation of part of the leg is required. </p> <p>Prostanoids make up a family of medicines that could increase blood supply to the legs when taken orally or by injection. Prostanoids expand and open up small blood vessels and reduce the activity of inflammatory cells and platelets, preventing blood clots. We wanted to discover the benefits and harms of prostanoids for people whose leg arteries are severely blocked with no chance for surgical unblocking. </p> <p><b>Review question</b> </p> <p>In this review, we studied the effect of prostanoids in people with severely blocked leg arteries who are not able to undergo any surgical unblocking procedure. </p> <p><b>Study characteristics</b> </p> <p>We searched published and unpublished studies up to January 2017. We found 33 clinical trials with a total of 4477 participants; most were published in the 1980s and 1990s and were carried out in European countries. Eleven out of 33 studies received funding from pharmaceutical companies. Most studies included patients over 60 years old who had severe blocking of arteries of the leg; many also had diabetes. Follow‐up was usually less than 1 year. </p> <p><b>Key results</b> </p> <p>We found that, when compared with placebo, prostanoids provided a small beneficial effect by alleviating pain in the leg at rest and improving ulcer healing. Prostanoids did not reduce deaths or the need for an amputation. We found that no studies evaluated the quality of life of people with this condition. We found insufficient evidence to compare effects of prostanoids against those of other medications or other prostanoids. </p> <p>Our findings suggest that taking prostanoids does cause harm. When 1000 patients are treated with prostanoids, on average 674 (572 to 798) will experience adverse events, compared with 319 given placebo. Adverse events usually include nausea, vomiting, diarrhoea, headache, dizziness, and flushing. More severe adverse events include low blood pressure, chest pain, and abnormalities in heart rhythm. </p> <p><b>Quality of the evidence</b> </p> <p>When evaluating effects of prostanoids on rest‐pain, ulcer healing, and adverse events, researchers provided moderate‐quality evidence; review authors downgraded this in most cases because of loss of participants to follow‐up. Evaluating cardiovascular mortality yielded evidence of low quality related to loss of participants to follow‐up and small numbers of reported events. On the other hand, the quality of evidence on risk of amputation was high. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006544-sec-0160" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006544-sec-0160"></div> <h3 class="title" id="CD006544-sec-0161">Implications for practice</h3> <section id="CD006544-sec-0161"> <p>We found low‐quality evidence suggesting that prostanoids had no effect on the incidence of cardiovascular mortality when compared against placebo, and high‐quality evidence showing that prostanoids had no effect on the incidence of total amputations for the same comparison. Moderate‐quality evidence showed beneficial effects of prostanoids for rest‐pain relief and ulcer healing when compared against placebo; however, effects on rest‐pain relief were diluted when studies with high risk of bias were excluded. Additionally, we found moderate‐quality evidence showing a greater incidence of adverse effects with the use of prostanoids. None of the included studies reported quality of life measurements. The main reasons for downgrading the quality of evidence were high risk of attrition bias and imprecision of the included studies. We found evidence of low to very low quality on effects of prostanoids versus other active agents or versus other prostanoids because a small number of studies evaluated the same comparisons and had high risk of bias. </p> <p>Current evidence regarding effects and safety of prostanoids for patients with critical limb ischaemia unsuitable for rescue or reconstructive interventions is insufficient to ascertain the balance of benefits and harms of this therapeutic strategy. Therefore, careful assessment of therapeutic alternatives should be considered. </p> </section> <h3 class="title" id="CD006544-sec-0162">Implications for research</h3> <section id="CD006544-sec-0162"> <p>Results of this comprehensive systematic review suggest that planning of further research on this topic should address weaknesses identified in the included studies, with the aim of improving the quality of evidence. As the main reasons for downgrading evidence were high risk of attrition bias and imprecision issues, future randomised clinical trialists should increase efforts to obtain optimal sample sizes and to prevent losses to follow‐up, with the goal of improving the precision of effect estimates. </p> <p>Additionally, future research should consider measurement of important patient‐centred outcomes such as quality of life, which was not addressed by any of the included studies. Use of validated instruments for measurement of objective outcomes such as ulcer healing and rest‐pain relief is imperative for preventing bias and increasing clinical consistency across studies. Finally, registration of protocols could prevent selective outcome reporting and risk of publication bias. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006544-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006544-sec-0022"></div> <div class="table" id="CD006544-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prostanoids compared with placebo for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Prostanoids compared with placebo for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> prostanoids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prostanoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality<br/> Follow‐up: range 2 months to 7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.41 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1170<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (13 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 1 month to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.86 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2825<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000<br/> (231 to 293) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 3 weeks to 7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.11<br/> (1.79 to 2.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>655<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>674 per 1000<br/> (572 to 798) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief (dichotomous)<br/> Follow‐up: range 1 month to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/> (1.06 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1179<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/> (241 to 362) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: range 3 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.24<br/> (1.04 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1719<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>358 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000<br/> (373 to 530) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because most studies were at high risk of bias (attrition bias).<br/> <sup>b</sup>Downgraded by one level for not meeting optimal information size (OIS) (for a 25% relative risk ratio (RRR), alpha = 0.05 and beta = 0.20, OIS = 13342). The 95% confidence interval includes both appreciable benefit and harm.<br/> <sup>c</sup>Even though eight trials were at high risk of attrition bias, a sensitivity analysis excluding those studies did not modify the effects of prostanoids (RR 0.91, 95% CI 0.75 to 1.10). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006544-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prostanoids compared with pentoxifylline for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Prostanoids compared with pentoxifylline for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> prostanoids<br/> <b>Comparison:</b> pentoxifylline </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pentoxifylline</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prostanoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.50<br/> (0.05 to 5.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (3 to 301) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.24 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/> (69 to 420) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/> (0.72 to 2.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000<br/> (206 to 777) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.61<br/> (1.13 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>828 per 1000<br/> (581 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels owing to high risk of performance bias (open‐label study) and attrition bias, and owing to imbalance in baseline characteristics of participants with no mention of methods used for random sequence generation or allocation concealment.<br/> <sup>b</sup>Downgraded by one level owing to wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006544-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prostanoids compared with naftidrofuryl for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Prostanoids compared with naftidrofuryl for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> prostanoids<br/> <b>Comparison:</b> naftidrofuryl </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with naftidrofuryl</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prostanoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 6 months to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.57 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1000<br/> (380 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 3 days to 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.29<br/> (0.27 to 40.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/> (10 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: range 3 weeks to 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.83 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>648 per 1000<br/> (502 to 841) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: range 3 weeks to 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.46 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>416 per 1000<br/> (197 to 870) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of attrition bias.<br/> <sup>b</sup>Downgraded by one level owing to imprecision issues (low rate of events).<br/> <sup>c</sup>Downgraded by one level owing to high risk of bias (one trial presented high risk of performance and detection bias, and the other high risk of attrition bias).<br/> <sup>d</sup>Downgraded by one level owing to high risk of bias (most studies presented high risk of performance and detection bias or performance bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006544-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PGE1 compared with ATP for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PGE<sub>1</sub> compared with ATP for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> PGE<sub>1</sub><br/> <b>Comparison:</b> ATP </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ATP</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PGE<sub>1</sub> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 3 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/> (0.09 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>91<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (28 to 229) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event (participants)<br/> Follow‐up: range 3 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.78<br/> (1.41 to 5.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>91<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 per 1000<br/> (269 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rest‐pain relief</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported rest‐pain as a continuous outcome. Reanalysis was not possible.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing (complete)<br/> Follow‐up: median 3 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/> (0.17 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000<br/> (39 to 699) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ATP: adenosine triphosphate; CI: confidence interval; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of attrition bias.<br/> <sup>b</sup>Downgraded by one level owing to a wide confidence interval resulting from a low rate of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006544-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PGE1 compared with inositol niacinate for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PGE<sub>1</sub> compared with inositol niacinate for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> PGE<sub>1</sub><br/> <b>Comparison:</b> inositol niacinate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inositol niacinate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PGE<sub>1</sub> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total amputations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events (participants)<br/> Follow‐up: range 2 weeks to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.60<br/> (0.79 to 3.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>65<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>533 per 1000<br/> (263 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: range 2 weeks to 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/> (0.88 to 2.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>725 per 1000<br/> (440 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Ulcer healing<br/> Follow‐up: range 2 weeks to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 3.06<br/> (0.41 to 22.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>65<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1000<br/> (23 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of attrition bias.<br/> <sup>b</sup>Downgraded by one level owing to a low rate of events resulting in wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006544-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Iloprost compared with PGE1 for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Iloprost compared with PGE<sub>1</sub> for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> iloprost<br/> <b>Comparison:</b> PGE<sub>1</sub> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PGE<sub>1</sub> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with iloprost</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 4 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.66 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>209<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>466 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000<br/> (308 to 564) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 2 days to 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.35<br/> (1.82 to 3.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1000<br/> (368 to 615) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: range 21 days to 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/> (0.90 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>491 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>565 per 1000<br/> (442 to 722) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: range 21 days to 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.24<br/> (0.95 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1000<br/> (509 to 873) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of bias (performance, detection, and attrition bias).<br/> <sup>b</sup>Downgraded by one level owing to a low rate of events resulting in a wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006544-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Clinprost compared with lipo‐PGE1 for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Clinprost compared with lipo‐PGE<sub>1</sub> for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> clinprost<br/> <b>Comparison:</b> lipo‐PGE<sub>1</sub> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with lipo‐PGE<sub>1</sub> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clinprost</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors mentioned the incidence of 1 death due to acute heart failure during the trial in the clinprost group. They did not discriminate whether this happened in the CLI from atherosclerotic origin group or in the thromboangiitis obliterans (TAO) group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total amputations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: median 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.83<br/> (0.56 to 5.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The trial authors did not discriminate whether adverse events happened in the CLI from atherosclerotic origin group or in the TAO group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/> (32 to 346) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: median 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.58 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>67<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1000<br/> (228 to 737) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: median 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.74 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>457 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>539 per 1000<br/> (338 to 864) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; CLI: critical limb ischaemia; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio; TAO: thromboangiitis obliterans. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to few events, resulting in a wide confidence interval that includes both harms and benefits.<br/> <sup>b</sup>Downgraded by one level owing to high risk of bias (attrition rate &gt; 10%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006544-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006544-sec-0023"></div> <section id="CD006544-sec-0024"> <h3 class="title" id="CD006544-sec-0024">Description of the condition</h3> <p>The term 'critical limb ischaemia' (CLI) should be used for all cases of chronic ischaemic rest‐pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease (<a href="./references#CD006544-bbs2-0069" title="Gerhard‐HermanMD , GornikHL , BarrettC , BarshesNR , CorriereMA , DrachmanDE , et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2016;69(11):1465‐508. [PUBMED: 27840333] ">Gerhard‐Herman 2016</a>). CLI stands at the end of the most severe spectrum of peripheral arterial obstructive disease (PAOD). This multi‐factorial condition occurs secondary to the combination of endothelial dysfunction, dyslipidaemia, inflammatory and immunological factors, plaque rupture, and tobacco use. Unlike individuals with intermittent claudication (IC), patients with CLI have poor arterial blood flow to the lower limbs (resting perfusion), which is inadequate to sustain viability in the distal tissue bed. The European Working Group on CLI specifically defined this illness as the presence of ischaemic rest‐pain requiring analgesia for longer than two weeks, or ulceration, or gangrene of the lower extremity with ankle systolic blood pressure &lt; 50 mmHg and/or toe systolic pressure &lt; 30 mmHg (<a href="./references#CD006544-bbs2-0058" title="Anonymous . Second European Consensus Document on chronic critical leg ischemia. Circulation1991;84(4 Suppl):1‐26. ">Anonymous 1991</a>). Although the definition of CLI has evolved over time (<a href="./references#CD006544-bbs2-0060" title="BeckerF , Robert‐EbadiH , RiccoJB , SetacciC , CaoP , deDonatoG , et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. European Journal of Vascular and Endovascular Surgery2011;42 (Suppl 2):S4‐12. [PUBMED: 22172472] ">Becker 2011</a>), a recent multi‐disciplinary consensus ‐ the Peripheral Academic Research Consortium ‐ maintained those classic haemodynamic thresholds for patients with ischaemic rest‐pain, but defined CLI haemodynamic thresholds for patients with tissue loss as ankle systolic blood pressure &lt; 70 mmHg and/or toe systolic pressure &lt; 50 mmHg. This consensus definition also considers alternative haemodynamic parameters, such as transcutaneous oxygen (TcPO<sub>2</sub>) (&lt; 20 mmHg for patients with ischaemic rest‐pain and &lt; 40 mmHg for patients with tissue loss) and skin perfusion pressure (&lt; 40 mmHg or &lt; 30 mmHg, respectively) (<a href="./references#CD006544-bbs2-0090" title="PatelMR , ConteMS , CutlipDE , DibN , GeraghtyP , GrayW , et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). Journal of the American College of Cardiology2015;65(9):931‐41. [PUBMED: 25744011] ">Patel 2015</a>). </p> <p>Peripheral arterial disease (PAD) affects approximately 12% of adults increasing to 20% in people aged 70 years or older (<a href="./references#CD006544-bbs2-0068" title="DuaA , LeeCJ . Epidemiology of peripheral arterial disease and critical limb ischemia. Techniques in Vascular and Interventional Radiology2016;19(2):91‐5. [PUBMED: 27423989] ">Dua 2016</a>). CLI is the initial clinical presentation in only 1% to 2% of cases of PAD, whereas 40% to 50% of those affected begin with atypical leg pain, and 10% to 35% with IC; 20% to 50% are asymptomatic. After five years of progressive functional impairment, a further 1% to 2% of PAD cases will result in CLI and eventual amputation (<a href="./references#CD006544-bbs2-0076" title="HirschAT , HaskalZJ , HertzerNR , BakalCW , GreagerMA , HalperinJL , et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease. Circulation2006;113(11):463‐654. ">Hirsch 2006</a>). However, a more recent meta‐analysis estimated the deterioration rate to be as high as 21% (95% confidence interval (CI) 12% to 29%) over five years (<a href="./references#CD006544-bbs2-0095" title="SigvantB , LundinF , WahlbergE . The risk of disease progression in peripheral arterial disease is higher than expected: a meta‐analysis of mortality and disease progression in peripheral arterial disease. European Journal of Vascular and Endovascular Surgery2016;51(3):395‐403. [PUBMED: 26777541] ">Sigvant 2016</a>). Published epidemiological data on this condition are remarkably variable owing to use of different definitions of CLI over time; this represents the main cause of difficulty for proper identification of arterial insufficiency causing signs and symptoms in a large number of patients for epidemiological studies (<a href="./references#CD006544-bbs2-0060" title="BeckerF , Robert‐EbadiH , RiccoJB , SetacciC , CaoP , deDonatoG , et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. European Journal of Vascular and Endovascular Surgery2011;42 (Suppl 2):S4‐12. [PUBMED: 22172472] ">Becker 2011</a>). </p> <p>Besides age (<a href="./references#CD006544-bbs2-0078" title="HyltonJR , SmithCA , LiCS , PevecWC . Octogenarians develop infrapopliteal arterial occlusive disease in the absence of traditional risk factors. Annals of Vascular Surgery2014;28(7):1712‐8. [PUBMED: 24858583] ">Hylton 2014</a>; <a href="./references#CD006544-bbs2-0089" title="OstchegaY , Paulose‐RamR , DillonCF , GuQ , HughesJP . Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999‐2004. Journal of the American Geriatrics Society2007;55(4):583‐9. [PUBMED: 17397438] ">Ostchega 2007</a>), the most important clinical predictors for CLI progression are smoking and diabetes (<a href="./references#CD006544-bbs2-0077" title="HowardDP , BanerjeeA , FairheadJF , HandsL , SilverLE , RothwellPM . Population‐based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation2015;132(19):1805‐15. [PUBMED: 26350058] ">Howard 2015</a>). The risk associated with smoking applies to all ages and increases with the number of cigarettes smoked. Major PAD deterioration occurs in people with claudication who are heavy smokers (<a href="./references#CD006544-bbs2-0059" title="AquinoR , JohnnidesC , MakarounM , WhittleJC , MulukVS , KelleyME , et al. Natural history of claudication: long‐term serial follow‐up study of 1244 claudicants. Journal of Vascular Surgery2001;34(6):962‐70. [PUBMED: 11743546] ">Aquino 2001</a>). Diabetes is associated with greater severity of PAOD in the lower limbs, especially in the arteries below the knee (<a href="./references#CD006544-bbs2-0081" title="JudeEB , OyiboSO , ChalmersN , BoultonAJ . Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care2001;24(8):1433‐7. [PUBMED: 11473082] ">Jude 2001</a>). People with claudication and diabetes are also at higher risk of amputation and mortality than those with IC but without diabetes (<a href="./references#CD006544-bbs2-0059" title="AquinoR , JohnnidesC , MakarounM , WhittleJC , MulukVS , KelleyME , et al. Natural history of claudication: long‐term serial follow‐up study of 1244 claudicants. Journal of Vascular Surgery2001;34(6):962‐70. [PUBMED: 11743546] ">Aquino 2001</a>; <a href="./references#CD006544-bbs2-0081" title="JudeEB , OyiboSO , ChalmersN , BoultonAJ . Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care2001;24(8):1433‐7. [PUBMED: 11473082] ">Jude 2001</a>). However, it is difficult to determine the true impact of this condition on the prognosis of patients with CLI for two reasons: (1) the proportion of patients with diabetes is variable in different studies assessing the natural history of CLI; and (2) diagnosis of CLI in patients with diabetes is challenging owing to frequent comorbid neuropathy and infectious complications, which may lead to tissue lesions (<a href="./references#CD006544-bbs2-0060" title="BeckerF , Robert‐EbadiH , RiccoJB , SetacciC , CaoP , deDonatoG , et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. European Journal of Vascular and Endovascular Surgery2011;42 (Suppl 2):S4‐12. [PUBMED: 22172472] ">Becker 2011</a>). </p> <p>The prognosis for limb and patient survival is variable in chronic CLI. The most important risk factors for amputation are those involved in progression to CLI (<a href="./references#CD006544-bbs2-0077" title="HowardDP , BanerjeeA , FairheadJF , HandsL , SilverLE , RothwellPM . Population‐based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation2015;132(19):1805‐15. [PUBMED: 26350058] ">Howard 2015</a>), as well as an ankle brachial index (ABI) below 0.5 (<a href="./references#CD006544-bbs2-0080" title="JelnesR , GaardstingO , Hougaard JensenK , BackgaardN , TonnesenKH , SchroederT , et al. Fate in intermittent claudication: outcome and risk factors. British Medical Journal (Clinical Research Ed.)1986;293(6555):1137‐40. ">Jelnes 1986</a>). Within a six‐month period, 20% of patients die, 35% live but require amputation, and the remaining 45% live with no immediate need for amputation (<a href="./references#CD006544-bbs2-0067" title="DormandyJA , RutherfordRB . Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter‐Society Consensus (TASC). Journal of Vascular Surgery2000;31(1 Pt 2):S1‐S296. ">Dormandy 2000</a>). Meta‐analysis of 10 case series and non‐interventional or placebo arms of randomised controlled trials revealed a mortality rate of 22% (95% CI 12% to 32%) and an amputation rate of 30% (95% CI 19% to 42%) after 12 to 18 months' follow‐up (<a href="./references#CD006544-bbs2-0056" title="Abu DabrhAM , SteffenMW , UndavalliC , AsiN , WangZ , ElaminMB , et al. The natural history of untreated severe or critical limb ischemia. Journal of Vascular Surgery2015;62(6):1642‐51.e3. [PUBMED: 26391460] ">Abu 2015</a>). Even though the strength of evidence on pooled estimates was low owing to high risk of bias, heterogeneity, and imprecision, these results are consistent with previous observations (<a href="./references#CD006544-bbs2-0067" title="DormandyJA , RutherfordRB . Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter‐Society Consensus (TASC). Journal of Vascular Surgery2000;31(1 Pt 2):S1‐S296. ">Dormandy 2000</a>; <a href="./references#CD006544-bbs2-0076" title="HirschAT , HaskalZJ , HertzerNR , BakalCW , GreagerMA , HalperinJL , et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease. Circulation2006;113(11):463‐654. ">Hirsch 2006</a>; <a href="./references#CD006544-bbs2-0088" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , et al. Inter‐Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery2007;33 (Suppl 1):S1‐75. [PUBMED: 17140820] ">Norgren 2007</a>) and with the findings of a more recent retrospective study, which reported a mortality rate of 15% among patients with CLI after one year, and 24% after two years' follow‐up (<a href="./references#CD006544-bbs2-0084" title="MelilloE , MichelettiL , NutiM , Dell'OmoG , BerchiolliR , AdamiD , et al. Long‐term clinical outcomes in critical limb ischemia ‐ a retrospective study of 181 patients. European Review for Medical and Pharmacological Sciences2016;20(3):502‐8. [PUBMED: 26914126] ">Melillo 2016</a>). </p> <p>The prognosis after amputation is even worse. According to the Second European Consensus Document on chronic CLI (<a href="./references#CD006544-bbs2-0058" title="Anonymous . Second European Consensus Document on chronic critical leg ischemia. Circulation1991;84(4 Suppl):1‐26. ">Anonymous 1991</a>), perioperative mortality varies between 5% and 10% for below‐knee amputation, and between 15% and 20% for above‐knee amputation, respectively. This information is consistent with that provided in more recent reports, which estimated in‐hospital mortality rates for minor and major amputees as 3.6% to 4.6% and 16.8% to 19.8%, respectively (<a href="./references#CD006544-bbs2-0083" title="MalyarNM , FreisingerE , MeyborgM , LudersF , FurstenbergT , KrogerK , et al. Low rates of revascularization and high in‐hospital mortality in patients with ischemic lower limb amputation: morbidity and mortality of ischemic amputation. Angiology2016;67(9):860‐9. [PUBMED: 26764367] ">Malyar 2016</a>; <a href="./references#CD006544-bbs2-0087" title="MoxeyPW , HofmanD , HinchliffeRJ , JonesK , ThompsonMM , HoltPJ . Epidemiological study of lower limb amputation in England between 2003 and 2008. British Journal of Surgery2010;97(9):1348‐53. [PUBMED: 20632310] ">Moxey 2010</a>). A second amputation is required in 30% of cases (<a href="./references#CD006544-bbs2-0088" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , et al. Inter‐Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery2007;33 (Suppl 1):S1‐75. [PUBMED: 17140820] ">Norgren 2007</a>), and full mobility is achieved in only 56% of patients who have a minor amputation and in 17% of those who have a major amputation (above‐ and below‐knee) one year after the procedure (<a href="./references#CD006544-bbs2-0097" title="SuckowBD , GoodneyPP , CambriaRA , BertgesDJ , Eldrup‐JorgensenJ , IndesJE , et al. Predicting functional status following amputation after lower extremity bypass. Annals of Vascular Surgery2012;26(1):67‐78. [PUBMED: 22176876] ">Suckow 2012</a>). Furthermore, it is well known that patients with PAD have elevated risks of myocardial infarction, congestive heart failure, stroke, transient ischaemic attack, and cardiovascular death (<a href="./references#CD006544-bbs2-0064" title="CriquiMH , AboyansV . Epidemiology of peripheral artery disease. Circulation Research2015;116(9):1509‐26. [PUBMED: 25908725] ">Criqui 2015</a>). </p> <p>Quality of life in patients with CLI is significantly impaired compared with that in the general population and in patients with less severe PAOD (<a href="./references#CD006544-bbs2-0096" title="SprengersRW , TeraaM , MollFL , deWitGA , van derGraafY , VerhaarMC . Quality of life in patients with no‐option critical limb ischemia underlines the need for new effective treatment. Journal of Vascular Surgery2010;52(4):843‐9, 849.e1. [PUBMED: 20598482] ">Sprengers 2010</a>). Psychological testing of these patients has typically disclosed quality of life indices similar to those of patients with cancer at critical or even terminal phases (<a href="./references#CD006544-bbs2-0057" title="AlbersM , FrateziAC , DeLucciaN . Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. Journal of Vascular Surgery1992;16(1):54‐9. ">Albers 1992</a>). Most people with CLI who experienced amputations have reported mobility limitations, rest‐pain (amputation‐related pain or ischaemic‐related pain in the affected or contralateral limb), and depression as prevalent domains undermining their quality of life (<a href="./references#CD006544-bbs2-0098" title="SuckowBD , GoodneyPP , NolanBW , VeeraswamyRK , GallagherP , CronenwettJL , et al. Domains that determine quality of life in vascular amputees. Annals of Vascular Surgery2015;29(4):722‐30. [PUBMED: 25725279] ">Suckow 2015</a>). Therefore, because of its negative impact on quality of life and poor prognosis in terms of both limb and patient survival, CLI is a critical health issue. </p> <p>First‐line therapeutic options for CLI are limited to percutaneous transluminal angioplasty or surgical revascularisation. Unfortunately, many patients with CLI are poor candidates for either procedure because of comorbidities or vascular anatomy (lack of conduit). These patients have only medical treatment as a therapeutic alternative, and amputation (when necessary) as the last chance to survive. </p> <p>Angiogenic factors have suggested favour for neovascularisation by increasing collateral circulation and enhancing blood flow to ischaemic limbs. Despite promising results of early studies assessing the efficacy of this innovative treatment, systematic reviews and meta‐analyses examining patients with PAD and CLI (<a href="./references#CD006544-bbs2-0073" title="HammerA , SteinerS . Gene therapy for therapeutic angiogenesis in peripheral arterial disease ‐ a systematic review and meta‐analysis of randomized, controlled trials. VASA Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases2013;42(5):331‐9. [PUBMED: 23989068] ">Hammer 2013</a>; <a href="./references#CD006544-bbs2-0085" title="MiaoYL , WuW , LiBW , FangWW , LiuY , LiL , et al. Clinical effectiveness of gene therapy on critical limb ischemia: a meta‐analysis of 5 randomized controlled clinical trials. Vascular and Endovascular Surgery2014;48(5‐6):372‐7. [PUBMED: 24951292] ">Miao 2014</a>) showed no significant differences between treatment and control groups in terms of amputation, mortality at one year, or wound healing at six months' follow‐up. </p> <p>Other therapeutic strategies for non‐surgical patients, such as autologous implantation of bone marrow mononuclear cells and spinal cord stimulation, have proved modestly effective in decreasing the amputation rate and reducing pain during variable periods of follow‐up (<a href="./references#CD006544-bbs2-0086" title="MoazzamiK , MoazzamiB , RoohiA , NedjatS , DolmatovaE . Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008347.pub3] ">Moazzami 2014</a>; <a href="./references#CD006544-bbs2-0101" title="UbbinkDT , VermeulenH . Spinal cord stimulation for non‐reconstructable chronic critical leg ischaemia. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD004001.pub3] ">Ubbink 2013</a>). However, the quality of evidence regarding these strategies is considered moderate. </p> </section> <section id="CD006544-sec-0025"> <h3 class="title" id="CD006544-sec-0025">Description of the intervention</h3> <p>Medical therapies that decrease pain, promote healing of skin lesions, and reduce the risk of amputation would be attractive alternatives for patients with CLI non‐suitable for revascularisation procedures. Several drugs have been used at this stage (e.g. cilostazol, pentoxifylline, naftidrofuryl) and have led to no significant benefit. Prostanoids have been used for treatment of individuals with PAD for longer than two decades because some trials have recommended their use (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0079" title="The ICAI Group. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open‐label trial with prostaglandin E1. Annals of Internal Medicine1999;130(5):412‐21. ">ICAI Group 1999</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0100" title="TrubesteinG , vonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. Vasa Supplementum1989;28:44‐9. ">Trubestein 1989</a>; <a href="./references#CD006544-bbs2-0102" title="VerstraeteM . prostaglandins in critical limb ischemia. Vascular Medicine Review1994;5(2):93‐5. ">Verstraete 1994</a>). This family of drugs consists of the following: prostaglandin E<sub>1</sub> (also referred to as PGE<sub>1</sub>, or alprostadil, generally by intravenous or intra‐arterial administration for 21 days); prostacyclin (also referred to as PGI<sub>2</sub>, or epoprostenol, by intravenous administration for four to seven days, or by intra‐arterial administration for 72 hours); iloprost (by intravenous administration for 14 to 28 days, oral for 28 days up to one year); lipo‐ecraprost (by intravenous administration for 50 days); and ciprostene (by intravenous administration for seven days). </p> </section> <section id="CD006544-sec-0026"> <h3 class="title" id="CD006544-sec-0026">How the intervention might work</h3> <p>Prostanoids have pharmacological activities on endothelial cells, vascular smooth muscle cells, and platelets that could favourably alter the otherwise inexorable downhill course of CLI. These include inhibition of platelet activation, adhesion, and aggregation; vasodilatation; vascular endothelial cytoprotection; and inhibition of leucocyte activation (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0079" title="The ICAI Group. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open‐label trial with prostaglandin E1. Annals of Internal Medicine1999;130(5):412‐21. ">ICAI Group 1999</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0092" title="RobertsonL , AndrasA . Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD000986.pub3] ">Robertson 2013</a>; <a href="./references#CD006544-bbs2-0100" title="TrubesteinG , vonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. Vasa Supplementum1989;28:44‐9. ">Trubestein 1989</a>). </p> </section> <section id="CD006544-sec-0027"> <h3 class="title" id="CD006544-sec-0027">Why it is important to do this review</h3> <p>A few meta‐analyses such as <a href="./references#CD006544-bbs2-0063" title="CreutzigA , LehmacherW , ElzeM . Meta‐analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa2004;33(3):137‐44. ">Creutzig 2004</a> and <a href="./references#CD006544-bbs2-0082" title="LoosemoreTM , ChalmersTC , DormandyJA . A meta‐analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. International Angiology1994;13(2):133‐42. ">Loosemore 1994</a> and reviews such as <a href="./references#CD006544-bbs2-0066" title="DormandyJA . Prostanoid drug therapy for peripheral arterial occlusive disease ‐ the European experience. Vascular Medicine1996;1(2):155‐8. ">Dormandy 1996</a> have been published, but they did not include all types of prostanoids and all routes of administration. The first version of this Cochrane review, published in 2010, took into account new approaches regarding this therapeutic option to find conclusive evidence about the effectiveness and safety of the whole family of prostanoids for patients with CLI, including only randomised controlled trials (RCTs) considered to have low or moderate risk of bias (<a href="./references#CD006544-bbs2-0105" title="RuffoloAJ , RomanoM , CiapponiA . Prostanoids for critical limb ischaemia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006544.pub2] ">Ruffolo 2010</a>). </p> <p>Even though other review authors have performed updated systematic reviews on this topic, their approaches were narrower in terms of interventions evaluated (<a href="./references#CD006544-bbs2-0061" title="BrodszkyV , FarkasK , JaraiZ , LandiA , PecsvaradyZ , BajiP , et al. Effectiveness of prostanoids in patients with critical leg ischemia [Prosztanoidok hatasossaga kritikus vegtagischaemiaban.]. Orvosi Hetilap2011;152(51):2047‐55. [PUBMED: 22130202] ">Brodszky 2011</a>), or broader in terms of study populations, including patients with PAOD of any severity (<a href="./references#CD006544-bbs2-0103" title="VitaleV , MonamiM , MannucciE . Prostanoids in patients with peripheral arterial disease: a meta‐analysis of placebo‐controlled randomized clinical trials. Journal of Diabetes and Its Complications2016;30(1):161‐6. [PUBMED: 26516035] ">Vitale 2016</a>). </p> <p>Moreover, since publication of the first version of this Cochrane systematic review, methodological standards have changed substantially. Currently, the preferred tool for appraisal of internal validity of RCTs is Cochrane's tool for assessing risk of bias (<a href="./references#CD006544-bbs2-0075" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>); use of any selection criterion based on a threshold of global quality assessment is discouraged. For these reasons, it is necessary to update this systematic review with the goal of reassessing eligibility of previously excluded studies and strength of evidence regarding effectiveness and safety of this pharmacological therapy. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006544-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006544-sec-0028"></div> <p>To determine the effectiveness and safety of prostanoids in patients with CLI unsuitable for rescue or reconstructive intervention. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006544-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006544-sec-0029"></div> <section id="CD006544-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006544-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials.</p> </section> <section id="CD006544-sec-0032"> <h4 class="title">Types of participants</h4> <p>People irrespective of age or gender, presenting with critical limb ischaemia of atherosclerotic origin, without chance of rescue or reconstructive intervention. We did not include studies with patients given a diagnosis of thromboangiitis obliterans, also known as Buerger's disease, unless more than 80% of participants fulfilled inclusion criteria, or disaggregated data were available for the group of participants with CLI of atherosclerotic origin. </p> </section> <section id="CD006544-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Prostaglandin E<sub>1</sub> (PGE<sub>1</sub>, alprostadil), prostacyclin (PGI<sub>2</sub>, epoprostenol), iloprost, beraprost, cisaprost, ciprostene, clinprost, ecraprost, or taprostene compared with placebo or other pharmacological control treatments (e.g. pentoxifylline, cilostazol, naftidrofuryl, angiogenic therapy, other prostanoids). We did not include surgical treatments or other medical non‐pharmacological treatments as comparators. </p> </section> <section id="CD006544-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD006544-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006544-list-0001"> <li> <p>Cardiovascular mortality (e.g. due to myocardial infarction, stroke, arrhythmia or variation form the normal rhythm of the heartbeat, sudden death) </p> </li> <li> <p>Total amputations (major plus minor)</p> </li> <li> <p>Quality of life (measured according to a validated quality of life questionnaire)</p> </li> <li> <p>Adverse events of treatment</p> </li> </ul> </p> </section> <section id="CD006544-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006544-list-0002"> <li> <p>Evaluation of rest‐pain and/or use of analgesic drugs (measured according to a validated pain scale and a validated questionnaire, respectively) </p> </li> <li> <p>Evolution of tissue lesions (healing or non‐healing ulcers, according to surface area increase or decrease, and presence or absence of granulation tissue) </p> </li> <li> <p>Major amputations (above or below knee)</p> </li> <li> <p>Minor amputations (partial feet or fingers)</p> </li> <li> <p>Ankle brachial index (ABI)</p> </li> <li> <p>All‐cause mortality</p> </li> </ul> </p> </section> </section> </section> <section id="CD006544-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not restrict language of publication.</p> <section id="CD006544-sec-0038"> <h4 class="title">Electronic searches</h4> <p>For this update, the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials. </p> <p> <ul id="CD006544-list-0003"> <li> <p>Cochrane Vascular Specialised Register (January 2017).</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1) via the Cochrane Register of Studies Online. </p> </li> </ul> </p> <p>See <a href="./appendices#CD006544-sec-0166">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Allied and Complementary Medicine Database (AMED), and through handsearching of relevant journals. A full list of databases, journals, and conference proceedings that have been searched, as well as the search strategies used, is presented in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in the Cochrane Library (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>The CIS and the review authors separately searched the following trial registries for details of ongoing and unpublished studies (January 2017). </p> <p> <ul id="CD006544-list-0004"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>International Standard Randomised Controlled Trials Number (ISRCTN) Registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> </ul> </p> <p>See <a href="./appendices#CD006544-sec-0167">Appendix 2</a> for details of the search strategies. </p> </section> <section id="CD006544-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We identified additional articles by reviewing reference lists of both papers identified by electronic searches and systematic reviews. We contacted pharmaceutical companies to ask about additional studies (Actelion Pharmaceuticals, Bayer‐Schering, Italfarmaco, Mitsubishi Pharma America, Pfizer, UCB Pharma, United Therapeutics). </p> </section> </section> <section id="CD006544-sec-0040"> <h3 class="title" id="CD006544-sec-0040">Data collection and analysis</h3> <section id="CD006544-sec-0041"> <h4 class="title">Selection of studies</h4> <p>For this update, two review authors (VV, JVAF or DC) independently checked titles, abstracts, and keywords of all references retrieved. We retrieved the full text of all studies considered potentially relevant, and each review author assessed these studies independently using a Study Eligibility Form. We resolved disagreements between the two review authors by consensus or, finally, by consultation with a third review author (AC). </p> </section> <section id="CD006544-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>For this update, two review authors (VV, JVAF, VS or DC) independently collected the following data from each included study using a Data Extraction Form, provided by Cochrane Vascular. </p> <p> <ul id="CD006544-list-0005"> <li> <p>Publication type and source, including language of publication, year of publication, and method of retrieval of the report. </p> </li> <li> <p>Sources of support.</p> </li> <li> <p>Trial design, including methods of generation and concealment of allocation sequences, along with type of control intervention. </p> </li> <li> <p>Setting, including country, and level of care.</p> </li> <li> <p>Participants, including selection criteria used and numbers of withdrawals and dropouts per group. </p> </li> <li> <p>Interventions, including dose, route of administration, and duration of treatment.</p> </li> <li> <p>Outcome measures, including modalities and schedules of assessment, adverse events, and overall mortality and details of its causes. </p> </li> <li> <p>Analysis, including whether analysis was done according to the intention‐to‐treat principle. </p> </li> <li> <p>Results, including averages and variations in individual outcome assessments and different comparisons, test statistics, and P values for comparison within and between groups. </p> </li> </ul> </p> <p>We resolved disagreements by consensus or by consultation with a third review author (AC), if required. We contacted primary study authors by email to obtain additional information. We collected all data in original units; therefore, transformation for comparisons was not necessary. </p> </section> <section id="CD006544-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this update, two review authors (VV, JVAF, VS, or DC) independently assessed potential risks of bias for all included RCTs using the Cochrane tool for assessing risk of bias (<a href="./references#CD006544-bbs2-0075" title="HigginsJPT , AltmanDG , SterneJAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). This tool assesses bias in six different domains. </p> <p> <ul id="CD006544-list-0006"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessors (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective outcome reporting (reporting bias).</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>Each domain received a score of high, low, or unclear risk of bias depending on each review author's judgement. We resolved disagreements by consensus and, if necessary, asked review author AC to act as arbitrator. We contacted study authors for clarification when doubt arose as to potential risk of bias. </p> </section> <section id="CD006544-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>Even though clinical heterogeneity was significant, we did perform an overall meta‐analysis of prostanoids versus placebo, including subgroup analysis by type of prostanoid. We also completed analyses of prostanoids versus other active agents by describing results of individual studies or performing meta‐analyses when more than one study reported the same outcome (prostanoids compared with pentoxifylline, naftidrofuryl, adenosine triphosphate (ATP), or inositol niacinate) and we considered results to show clinical homogeneity. In addition, we completed analyses of prostanoids versus other prostanoids for the specific comparisons described in the included studies (iloprost vs PGE<sub>1</sub>, clinprost vs lipo‐PGE<sub>1</sub>). Finally, we prepared a qualitative synthesis of reported adverse events by type of prostanoid. </p> <p>We analysed dichotomous data by using risk ratios (RRs) with a confidence interval (CI) of 95%. We analysed continuous data by using standardised mean differences (SMDs) with a CI of 95%. </p> </section> <section id="CD006544-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>For this update, we considered the individual participant as the unit of analysis. In the event that outcome information was reported as numbers of events instead of numbers of participants with at least one event, we did not include the study in the meta‐analysis. </p> </section> <section id="CD006544-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>In the event that data were missing from the full reports, we planned to move the study to Studies awaiting classification until we could obtain further information from the study authors. However, in four cases (potentially relevant studies published as abstracts), authors did not have the data, or did not reply, so we excluded their reports (<a href="./references#CD006544-bbs2-0042" title="FonsecaV , DandonaP , BelcherG . Treatment of ischaemic ulceration or rest pain with intravenous Iloprost: a double‐blind placebo controlled study. Diabetes 401991;Suppl 1:522A. ">Fonseca 1991</a>; <a href="./references#CD006544-bbs2-0045" title="MenzoianJ . Alprostadil in the treatment of patients with severe peripheral arterial occlusive disease (PAOD) not amenable to surgery: results of a randomized, placebo‐controlled multicenter study. International Angiology1995;14(Suppl 1):104. ">Menzoian 1995</a>; <a href="./references#CD006544-bbs2-0046" title="MingardiR , RumorF , StrazzaboscoM , et al. Medical therapy in diabetic angiopathy with inoperable critical limb ischemia (CLI) ‐ a randomized, between‐patients study to compare the effects of iloprost (I) vs pentoxyfilline (P). Thrombosis and Haemostasis1993;69(6):1243. ">Mingardi 1993</a>; <a href="./references#CD006544-bbs2-0052" title="SchwarzE , RattiR , DuranteF , BuskermolenM , BrighentiG . Iloprost vs nitrates and aspirin in the treatment of geriatric patients suffering of peripheral arterial obliterative disease. International Angiology1995;14(Suppl 1):201. ">Schwarz 1995</a>). We excluded another seven studies because trial authors reported only outcome measures combining participants with non‐critical limb ischaemia or with chance of reconstructive intervention and did not reply to our request for disaggregate data (<a href="./references#CD006544-bbs2-0036" title="BerteleV . Prostanoids for chronic critical leg ischemia. A randomized, controlled, open‐label trial with prostaglandin E1. Annals of Internal Medicine1999;130(5):412‐21. ">Bertele 1999</a>; <a href="./references#CD006544-bbs2-0041" title="FengK , TanJF , ChenY . Treatment of lower extremity diabetic atherosclerotic obliterans with shuxuetong injection. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban2009; Vol. 29, issue 3:255‐7. [CN‐00749881] ">Feng 2009</a>; <a href="./references#CD006544-bbs2-0043" title="GuanH , WangY , ZhangB , YeW , FuW , LiangW , et al. Comparison of beraprost and ticlopidine in Chinese patients with chronic peripheral arterial occlusion: a multicenter, single blind, randomized, controlled study. Current Therapeutic Research2003;64(7):488‐503. ">Guan 2003</a>; <a href="./references#CD006544-bbs2-0044" title="HeidrichH , BrodelC , MeucheC , HellmanM , RanftJ . Controlled long‐term blood pressure measurement with intravenous prostaglandin E1 infusion [Kontrollierte blutdrucklangzeitmessung unter intravenoser prostaglandin‐E1‐infusion]. VASA1991;20(1):13‐6. ">Heidrich 1991</a>; <a href="./references#CD006544-bbs2-0049" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS . Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study. Nephrology Dialysis Transplantation Plus2010;3:iii487. OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al. Randomized pilot trial between prostaglandin I2 analog and anti‐platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis and Dialysis2014; Vol. 18, issue 1:1‐8. [DOI: 10.1111/1744‐9987.12051; CN‐00978202] ">Ohtake 2014</a>). </p> </section> <section id="CD006544-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>To test for statistical heterogeneity, although of limited power, we used the Chi² test with significance level set at P &lt; 0.1 and the I² test. We interpreted the I² test as indicated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006544-bbs2-0074" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <p> <ul id="CD006544-list-0007"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: represents considerable heterogeneity.</p> </li> </ul> </p> <p>For robustness of results, and to perform a conservative analysis, if I² was 0% to 40%, suggesting not important heterogeneity, we reported results using a fixed‐effect model; if moderate heterogeneity was suggested by an I² between 30% and 60%, we reported results using a random‐effects model; and if I² was &gt; 50%, suggesting substantial heterogeneity, we did not perform meta‐analyses. </p> </section> <section id="CD006544-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting. When study protocols were unavailable, we compared methods and results sections of the report. </p> <p>We used funnel plots to assess small‐study effects when 10 or more studies were available for outcomes (<a href="./references#CD006544-bbs2-0074" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Several explanations can be offered for asymmetry in a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias. We interpreted these results carefully. </p> </section> <section id="CD006544-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We performed random‐effects meta‐analysis when we found little evidence of clinical heterogeneity across studies. Additionally, when we found good evidence of homogeneous effects across studies, we performed fixed‐effect meta‐analysis (see <a href="#CD006544-sec-0047">Assessment of heterogeneity</a>). We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006544-bbs2-0074" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method, and for continuous outcomes, we used the inverse variance method. We used Review Manager 5 (<a href="./references#CD006544-bbs2-0091" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) software to perform analyses. </p> </section> <section id="CD006544-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>When sufficient studies were available, we conducted subgroup analyses by type of prostanoid. We used the test for subgroup differences in Review Manager 5 (<a href="./references#CD006544-bbs2-0091" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to compare subgroups. </p> </section> <section id="CD006544-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of risk of bias on treatment effect sizes by excluding studies with high risk of bias in the following domains: allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessors (detection bias), and incomplete outcome data (attrition bias). </p> <section id="CD006544-sec-0052"> <h5 class="title">'Summary of findings' table</h5> <p>We presented the overall quality of evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD006544-bbs2-0071" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , SchünemannHJ . GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE] '>Guyatt 2008</a>), which takes into account five criteria. </p> <p> <ul id="CD006544-list-0008"> <li> <p>Risk of bias.</p> </li> <li> <p>Inconsistency.</p> </li> <li> <p>Imprecision.</p> </li> <li> <p>Publication bias.</p> </li> <li> <p>Directness of results.</p> </li> </ul> </p> <p>For each comparison, two review authors (VV and JVAF) independently rated the quality of evidence for each outcome as 'high', 'moderate', 'low', or 'very low' using <a href="./references#CD006544-bbs2-0070" title="GRADEpro GDT: GRADEpro Guideline Development Tool [Computer program]. Version accessed May 2017. Hamilton (ON): McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org. ">GRADEpro GDT</a>. We resolved discrepancies by consensus, or, if needed, by arbitration provided by a third review author (AC). For each comparison presented in the review, we presented a summary of evidence for main outcomes in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of overall confidence in effect estimates for each outcome (<a href="./references#CD006544-bbs2-0072" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ . GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026] ">Guyatt 2011</a>; <a href="./references#CD006544-bbs2-0093" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). When meta‐analysis was not possible, we presented results in a narrative 'Summary of findings' table. </p> <p>We included in the 'Summary of findings' table data for all participants with critical limb ischaemia for the following outcomes. </p> <p> <ul id="CD006544-list-0009"> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Amputations (total: major and minor).</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>Rest‐pain relief.</p> </li> <li> <p>Ulcer healing.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006544-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006544-sec-0053"></div> <section id="CD006544-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD006544-sec-0055"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD006544-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD006544-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram.*Out of 22 excluded studies, nine studies evaluated an inappropriate intervention for control group, seven included participants not fulfilling inclusion criteria with no available disaggregated outcome data, four were abstracts with no available full text, one had a quasi‐randomised design, and another was unpublished and had no available results." data-id="CD006544-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> <p>*Out of 22 excluded studies, nine studies evaluated an inappropriate intervention for control group, seven included participants not fulfilling inclusion criteria with no available disaggregated outcome data, four were abstracts with no available full text, one had a quasi‐randomised design, and another was unpublished and had no available results. </p> </div> </div> </div> <p>For this update, we reassessed all 39 previously included (20) and excluded (19) studies for eligibility according to changes in selection criteria. We reclassified one previously included study as a duplicate report (<a href="./references#CD006544-bbs2-0065" title="DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1987</a>), reclassified another previously included study as excluded owing to inappropriate intervention for the control group (<a href="./references#CD006544-bbs2-0035" title="BeischerW , DembskiJC , GrussJD , HofgartnerF , HorschA , HorschS , et al. Low‐dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1998;27(1):15‐9. ">Beischer 1998</a>), and reclassified seven previously excluded studies as included studies (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). We made no change to the other studies. </p> </section> <section id="CD006544-sec-0056"> <h4 class="title">Included studies</h4> <p>We have listed details of the included studies below and in the <a href="./references#CD006544-sec-0177" title="">Characteristics of included studies</a> table. </p> <p>For this update, we reassessed seven previously excluded studies for inclusion (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>), and we identified eight new included studies (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>). We reclassified one previously included study (<a href="./references#CD006544-bbs2-0065" title="DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1987</a>) as a preliminary report of another included study (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>), based on information provided by personal contact with study authors. We reclassified another previously included study as excluded owing to inappropriate intervention for the control group (<a href="./references#CD006544-bbs2-0035" title="BeischerW , DembskiJC , GrussJD , HofgartnerF , HorschA , HorschS , et al. Low‐dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1998;27(1):15‐9. ">Beischer 1998</a>). </p> <p>In total, we included in the review 33 trials with a total of 4477 randomised participants (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). </p> <p>Most studies were published in English, but nine were published in German (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>), one in Japanese (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>), and one in Italian (<a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>). We obtained information from the ClinicalTrials.gov database on the unpublished clinical trial <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>. </p> <p>We included 21 studies that compared a prostanoid versus placebo intravenously administered: seven studies on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), three on PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>), six on iloprost (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), and three single studies on lipo‐ecraprost (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>), taprostene (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>), or ciprostene (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>). Two additional studies compared high‐dose and low‐dose oral iloprost versus placebo (<a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>). </p> <p>Five studies compared PGE<sub>1</sub> against other active drugs. One study compared PGE<sub>1</sub> infused intravenously (iv) versus pentoxifylline (<a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>), and another compared the same prostanoid versus naftidrofuryl (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>). Another two studies compared intra‐arterial (ia) administered PGE<sub>1</sub> versus adenosine triphosphate (ATP) (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>), and a third compared high‐dose and low‐dose PGE<sub>1</sub> infused ia versus oral inositol niacinate (<a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>). </p> <p>Two studies compared PGI<sub>2</sub> versus naftidrofuryl: One used the ia route of administration (through a 21 spring wire guide (SWG) catheter inserted into the common femoral artery) (<a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>), and the other used the iv route (<a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>). </p> <p>Finally, five studies compared different prostanoids: Four studies evaluated iv iloprost versus PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>), and another compared TTC‐909 (clinprost incorporated in lipid microspheres) versus lipo‐PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>), both administered iv. </p> <p>No studies evaluating beraprost or cisaprost fulfilled the inclusion criteria.</p> <p>Length of treatment ranged from three days to four weeks, except for one cross‐over study, for which length of treatment was three hours with a washout period of one day between interventions (<a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>). Length of participant follow‐up ranged from two weeks to six months, except for two studies, in which follow‐up lasted three years and four years (<a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a> and <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>, respectively). </p> </section> <section id="CD006544-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We have listed details of excluded studies in the <a href="./references#CD006544-sec-0178" title="">Characteristics of excluded studies</a> table. </p> <p>For this update, we identified nine new excluded studies (<a href="./references#CD006544-bbs2-0040" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Clinical study of TTC‐909 (Prostacyclin derivative, clinprost incorporated in lipid microspheres) in patients with peripheral arterial occlusive disease: establishment of optimal dose in multi‐center double‐blind comparative study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1995; Vol. 11, issue 10:2083‐110. [CN‐00543531] EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Clinical study of TTC‐909 (Prostacyclin derivative, clinprost incorporated in lipid microspheres) in patients with peripheral arterial occlusive disease: establishment of optimal dose in multi‐center double‐blind comparative study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1997; Vol. 13, issue 21:5595‐622. [CN‐00543608] ">Esato 1997</a>; <a href="./references#CD006544-bbs2-0041" title="FengK , TanJF , ChenY . Treatment of lower extremity diabetic atherosclerotic obliterans with shuxuetong injection. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban2009; Vol. 29, issue 3:255‐7. [CN‐00749881] ">Feng 2009</a>; <a href="./references#CD006544-bbs2-0047" title="Efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease [A double‐blind, randomized, placebo‐controlled study to assess the efficacy and safety of CirculaseTM for the treatment of critical leg ischemia]. clinicaltrials.gov/ct2/show/NCT00059644. Date first received: 29 April 2003. ">NCT00059644</a>; <a href="./references#CD006544-bbs2-0048" title="NizankowskiR , KrólikowskiW , BielatowiczJ , SzczeklikA . Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thrombosis Research1985; Vol. 37, issue 1:21‐8. [CN‐00037548] ">Nizankowski 1985</a>; <a href="./references#CD006544-bbs2-0049" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS . Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study. Nephrology Dialysis Transplantation Plus2010;3:iii487. OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al. Randomized pilot trial between prostaglandin I2 analog and anti‐platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis and Dialysis2014; Vol. 18, issue 1:1‐8. [DOI: 10.1111/1744‐9987.12051; CN‐00978202] ">Ohtake 2014</a>; <a href="./references#CD006544-bbs2-0051" title="Sakaguchi‐Shukichi . Evaluation of the efficacy of beraprost sodium (PGI2 analogue) in chronic arterial occlusion: a double‐blind comparative study with ticlopidine hydrochloride. Rinsho to Kenkyu1990; Vol. 67:575‐84. [CN‐00740416] ">Sakaguchi‐Shukichi 1990</a>; <a href="./references#CD006544-bbs2-0053" title="SertM , SoydasB , AikimbaevK , TetikerT . Effects of iloprost (a prostacyclin analogue) on the endothelial dysfunction and foot ulcers in diabetic patients with peripheral arterial disease. International Journal of Diabetes and Metabolism2008; Vol. 16, issue 1:7‐11. [CN‐00754583] ">Sert 2008</a>; <a href="./references#CD006544-bbs2-0054" title="WeissT , GriesshaberJ , RogattiW , KistnerO , HsuE , JansenT , et al. Effect of intra‐arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities. VASA Supplementum1991; Vol. 33:341‐2. [CN‐00081779] ">Weiss 1991</a>; <a href="./references#CD006544-bbs2-0055" title="YlitaloP , KaukinenS , ReinikainenP , SaleniusJP , VapaataloH . A randomized, double‐blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. International Journal of Clinical Pharmacology, Therapy, and Toxicology1990; Vol. 28, issue 5:197‐204. [CN‐00068745] ">Ylitalo 1990</a>). We reclassified one previously included study as excluded (<a href="./references#CD006544-bbs2-0035" title="BeischerW , DembskiJC , GrussJD , HofgartnerF , HorschA , HorschS , et al. Low‐dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1998;27(1):15‐9. ">Beischer 1998</a>). We also reclassified and included seven studies that were excluded in the previous review owing to high risk of bias (see <a href="#CD006544-sec-0056">Included studies</a>), making a total of 22 excluded studies. </p> <p>Among the 22 excluded studies, the most frequent criteria for exclusion were inappropriate or no intervention for the control group (<a href="./references#CD006544-bbs2-0034" title="ArosioE , SardinaM , PriorM , DeMarchiS , ZannoniM , BianchiniC . Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche‐Fontaine stage III. European Review for Medical and Pharmacological Sciences1998;2(2):53‐9. ">Arosio 1998</a>; <a href="./references#CD006544-bbs2-0035" title="BeischerW , DembskiJC , GrussJD , HofgartnerF , HorschA , HorschS , et al. Low‐dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1998;27(1):15‐9. ">Beischer 1998</a>; <a href="./references#CD006544-bbs2-0037" title="BreuerC , AbriO . Prostacyclin (iloprost) as an adjuvant in local surgical therapy of stage IV arterial occlusive disease ‐ is quantification of the therapeutic effect possible with tcPO2 measurements?. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases1995;24(1):62‐71. ">Breuer 1995</a>; <a href="./references#CD006544-bbs2-0038" title="CerielloA , SardinaM , MotzE , LizzioS , TunizD , BianchiniC . Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche‐Fontaine stage III. International Journal of Angiology1998;7(1):28‐33. ">Ceriello 1998</a>; <a href="./references#CD006544-bbs2-0039" title="DiPaoloN , BocciV , SalvoDP , PalascianoG , BiagioliM , MeiniS , et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. International Journal of Artificial Organs2005;28(10):1039‐50. ">Di Paolo 2005</a>; <a href="./references#CD006544-bbs2-0040" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Clinical study of TTC‐909 (Prostacyclin derivative, clinprost incorporated in lipid microspheres) in patients with peripheral arterial occlusive disease: establishment of optimal dose in multi‐center double‐blind comparative study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1995; Vol. 11, issue 10:2083‐110. [CN‐00543531] EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Clinical study of TTC‐909 (Prostacyclin derivative, clinprost incorporated in lipid microspheres) in patients with peripheral arterial occlusive disease: establishment of optimal dose in multi‐center double‐blind comparative study. Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)1997; Vol. 13, issue 21:5595‐622. [CN‐00543608] ">Esato 1997</a>; <a href="./references#CD006544-bbs2-0050" title="PetronellaP , FredaF , NunziataL , AntropoliM , ManganielloA , CutoloPP , et al. Prostaglandin E1 versus lumbar sympathectomy in the treatment of peripheral arterial occlusive disease: randomised study of 86 patients. Nutrition, Metabolism, and Cardiovascular Diseases2004;14(4):186‐92. ">Petronella 2004</a>; <a href="./references#CD006544-bbs2-0053" title="SertM , SoydasB , AikimbaevK , TetikerT . Effects of iloprost (a prostacyclin analogue) on the endothelial dysfunction and foot ulcers in diabetic patients with peripheral arterial disease. International Journal of Diabetes and Metabolism2008; Vol. 16, issue 1:7‐11. [CN‐00754583] ">Sert 2008</a>; <a href="./references#CD006544-bbs2-0054" title="WeissT , GriesshaberJ , RogattiW , KistnerO , HsuE , JansenT , et al. Effect of intra‐arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities. VASA Supplementum1991; Vol. 33:341‐2. [CN‐00081779] ">Weiss 1991</a>) and participants not fulfilling inclusion criteria with no available disaggregated outcome data (<a href="./references#CD006544-bbs2-0036" title="BerteleV . Prostanoids for chronic critical leg ischemia. A randomized, controlled, open‐label trial with prostaglandin E1. Annals of Internal Medicine1999;130(5):412‐21. ">Bertele 1999</a>; <a href="./references#CD006544-bbs2-0041" title="FengK , TanJF , ChenY . Treatment of lower extremity diabetic atherosclerotic obliterans with shuxuetong injection. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese Journal of Integrated Traditional and Western Medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban2009; Vol. 29, issue 3:255‐7. [CN‐00749881] ">Feng 2009</a>; <a href="./references#CD006544-bbs2-0043" title="GuanH , WangY , ZhangB , YeW , FuW , LiangW , et al. Comparison of beraprost and ticlopidine in Chinese patients with chronic peripheral arterial occlusion: a multicenter, single blind, randomized, controlled study. Current Therapeutic Research2003;64(7):488‐503. ">Guan 2003</a>; <a href="./references#CD006544-bbs2-0044" title="HeidrichH , BrodelC , MeucheC , HellmanM , RanftJ . Controlled long‐term blood pressure measurement with intravenous prostaglandin E1 infusion [Kontrollierte blutdrucklangzeitmessung unter intravenoser prostaglandin‐E1‐infusion]. VASA1991;20(1):13‐6. ">Heidrich 1991</a>; <a href="./references#CD006544-bbs2-0048" title="NizankowskiR , KrólikowskiW , BielatowiczJ , SzczeklikA . Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thrombosis Research1985; Vol. 37, issue 1:21‐8. [CN‐00037548] ">Nizankowski 1985</a>; <a href="./references#CD006544-bbs2-0049" title="OhtakeT , SatoM , NakazawaR , KondohM , KobayashiS . Effect of beraprost sodium (PGI2 analogue) on peripheral arterial disease (PAD) in patients on hemodialysis: result from a multicenter randomized prospective interventional study. Nephrology Dialysis Transplantation Plus2010;3:iii487. OhtakeT , SatoM , NakazawaR , KondohM , MiyajiT , MoriyaH , et al. Randomized pilot trial between prostaglandin I2 analog and anti‐platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic Apheresis and Dialysis2014; Vol. 18, issue 1:1‐8. [DOI: 10.1111/1744‐9987.12051; CN‐00978202] ">Ohtake 2014</a>; <a href="./references#CD006544-bbs2-0055" title="YlitaloP , KaukinenS , ReinikainenP , SaleniusJP , VapaataloH . A randomized, double‐blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. International Journal of Clinical Pharmacology, Therapy, and Toxicology1990; Vol. 28, issue 5:197‐204. [CN‐00068745] ">Ylitalo 1990</a>). Four out of 22 studies were abstracts for which we were unable to obtain full text in spite of contacting trial authors for further information (<a href="./references#CD006544-bbs2-0042" title="FonsecaV , DandonaP , BelcherG . Treatment of ischaemic ulceration or rest pain with intravenous Iloprost: a double‐blind placebo controlled study. Diabetes 401991;Suppl 1:522A. ">Fonseca 1991</a>; <a href="./references#CD006544-bbs2-0045" title="MenzoianJ . Alprostadil in the treatment of patients with severe peripheral arterial occlusive disease (PAOD) not amenable to surgery: results of a randomized, placebo‐controlled multicenter study. International Angiology1995;14(Suppl 1):104. ">Menzoian 1995</a>; <a href="./references#CD006544-bbs2-0046" title="MingardiR , RumorF , StrazzaboscoM , et al. Medical therapy in diabetic angiopathy with inoperable critical limb ischemia (CLI) ‐ a randomized, between‐patients study to compare the effects of iloprost (I) vs pentoxyfilline (P). Thrombosis and Haemostasis1993;69(6):1243. ">Mingardi 1993</a>; <a href="./references#CD006544-bbs2-0052" title="SchwarzE , RattiR , DuranteF , BuskermolenM , BrighentiG . Iloprost vs nitrates and aspirin in the treatment of geriatric patients suffering of peripheral arterial obliterative disease. International Angiology1995;14(Suppl 1):201. ">Schwarz 1995</a>). Finally, one study was non‐randomised (<a href="./references#CD006544-bbs2-0051" title="Sakaguchi‐Shukichi . Evaluation of the efficacy of beraprost sodium (PGI2 analogue) in chronic arterial occlusion: a double‐blind comparative study with ticlopidine hydrochloride. Rinsho to Kenkyu1990; Vol. 67:575‐84. [CN‐00740416] ">Sakaguchi‐Shukichi 1990</a>), and another was unpublished and no results were available (<a href="./references#CD006544-bbs2-0047" title="Efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease [A double‐blind, randomized, placebo‐controlled study to assess the efficacy and safety of CirculaseTM for the treatment of critical leg ischemia]. clinicaltrials.gov/ct2/show/NCT00059644. Date first received: 29 April 2003. ">NCT00059644</a>). </p> </section> </section> <section id="CD006544-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>None of the included studies presented low risk of bias in all domains, and most studies presented at least one domain with high risk of bias (see <a href="./references#CD006544-sec-0177" title="">Characteristics of included studies</a>; <a href="#CD006544-fig-0002">Figure 2</a>; and <a href="#CD006544-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD006544-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD006544-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006544-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006544-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD006544-sec-0059"> <h4 class="title">Allocation</h4> <p>Of the 33 included studies, six (18%) described the method used for the randomisation process (see <a href="./references#CD006544-sec-0177" title="">Characteristics of included studies</a>). One study used a random number table (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>), three used a computer‐generated randomisation list (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>), one study reported use of random numbers (<a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>), and another stated that investigators used a randomised, permuted block design (<a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>). The remaining studies did not provide sufficient information, and we deemed that they had unclear risk of bias. </p> <p>Seven studies (21%) provided an explanation of the allocation concealment process. Five studies described use of an adequate method for allocation concealment, which included central allocation (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>), a sealed packaging method (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>), and a code of drug assignment supplied by the study sponsor (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>). Two studies reported that researchers used a randomisation or allocation list (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>); we therefore considered them to have high risk of bias. The remaining studies did not provide sufficient information, and we deemed that they had unclear risk of bias. </p> </section> <section id="CD006544-sec-0060"> <h4 class="title">Blinding</h4> <p>Of the 33 included studies, 21 (64%) reported a double‐blind design, and we considered them to be at low risk of performance bias (see <a href="./references#CD006544-sec-0177" title="">Characteristics of included studies</a>). Seven studies (21%) were open‐label studies; we therefore considered them to have high risk of bias owing to the subjective nature of reported outcomes (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). Five studies (15%) provided no statement or information about blinding (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>), and we deemed that they were at unclear risk of bias. </p> <p>Among the 21 studies described by trial authors as double‐blind, 10 stated that not only participants and study personnel, but also outcome assessors, were blinded (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>); we therefore considered them to be at low risk of detection bias. The remaining 11 studies (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>) did not mention whether outcome assessors were blinded; therefore we considered them to be at unclear risk of detection bias. We considered the seven open‐label studies to be at high risk of bias in this domain as they did not include a blinded outcome assessor (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). Five studies (15%) provided no statement or information about blinding of outcome assessment (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>); we deemed that these studies had unclear risk of bias. </p> </section> <section id="CD006544-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Of the 33 studies included, 30 (90%) reported participant withdrawals (see <a href="./references#CD006544-sec-0177" title="">Characteristics of included studies</a>). Twenty‐one (64%) studies had high risk of bias in this domain: 16 described an attrition rate greater than 10% (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>), one reported unbalanced withdrawals in the control group (<a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>), and four did not perform intention‐to‐treat (ITT) analysis (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). Four studies did not provide sufficient information, and we deemed that they were at unclear risk of bias in this domain (<a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>); we considered the remaining eight studies to have low risk of attrition bias owing to complete follow‐up or attrition rate less than 10% and ITT analysis (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>). </p> </section> <section id="CD006544-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Of the 33 studies included, 28 (85%) reported all outcomes specified in the methods section (see <a href="./references#CD006544-sec-0177" title="">Characteristics of included studies</a>). We considered three studies as having high risk of selective reporting bias because we noted differences between outcomes reported in the methods and results sections (<a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>); because only the composite efficacy outcome was reported (<a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>); or because reported outcomes were subjective and were not clearly defined (<a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>). Two studies did not provide prespecified outcomes in the methods section (<a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>); we deemed that they had unclear risk of bias. </p> <p>One of the included studies is a report of adverse events of a larger efficacy study, which we could not retrieve by applying search strategies and contacting trial authors (<a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>). </p> <p>Regarding publication bias, we did not detect important asymmetries in the following outcomes from funnel plots performed for meta‐analyses, including at least 10 studies that compared prostanoids versus placebo: total amputations (<a href="#CD006544-fig-0004">Figure 4</a>), all‐cause mortality, rest‐pain relief (dichotomous variable), and ulcer healing. </p> <div class="figure" id="CD006544-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Prostanoids versus placebo, outcome: 1.2 Total amputations." data-id="CD006544-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Prostanoids versus placebo, outcome: 1.2 Total amputations.</p> </div> </div> </div> </section> <section id="CD006544-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>We considered two studies to have low risk of bias because trial authors provided a complete description of baseline characteristics of included participants and identical care programmes for both groups (<a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>). One study presented unbalanced baseline characteristics and co‐interventions between groups (<a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>), and another was terminated early because of futility (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>); therefore we considered these studies to have high risk of bias. </p> <p>The remaining 29 studies presented unclear risk of bias in this domain as the result of incomplete description of care programmes and baseline risk of included participants (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>; <a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). </p> </section> </section> <section id="CD006544-sec-0064"> <h3 class="title" id="CD006544-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD006544-tbl-0001"><b>Summary of findings for the main comparison</b> Prostanoids compared with placebo for critical limb ischaemia</a>; <a href="./full#CD006544-tbl-0002"><b>Summary of findings 2</b> Prostanoids compared with pentoxifylline for critical limb ischaemia</a>; <a href="./full#CD006544-tbl-0003"><b>Summary of findings 3</b> Prostanoids compared with naftidrofuryl for critical limb ischaemia</a>; <a href="./full#CD006544-tbl-0004"><b>Summary of findings 4</b> PGE<sub>1</sub> compared with ATP for critical limb ischaemia</a>; <a href="./full#CD006544-tbl-0005"><b>Summary of findings 5</b> PGE<sub>1</sub> compared with inositol niacinate for critical limb ischaemia</a>; <a href="./full#CD006544-tbl-0006"><b>Summary of findings 6</b> Iloprost compared with PGE<sub>1</sub> for critical limb ischaemia</a>; <a href="./full#CD006544-tbl-0007"><b>Summary of findings 7</b> Clinprost compared with lipo‐PGE<sub>1</sub> for critical limb ischaemia</a> </p> <section id="CD006544-sec-0065"> <h4 class="title">Prostanoids versus placebo</h4> <p>As we could obtain neither concrete nor homogeneous definitions of some of the predefined outcomes, we considered the following outcomes as a dichotomous outcome: evaluation of rest‐pain relief when it was reported as the number or proportion of participants who experienced any improvement on a pain scale (considered no relief if pain was the same or worse); and ulcer healing when it was reported as the number or proportion of participants who had any decrease in surface area and/or presence of granulation tissue (considered no healing if surface area was similar or bigger and/or granulation tissue was absent). </p> <p>Although we noted some clinical heterogeneity (study designs, types of prostanoid, and routes of administration differed significantly among included studies), we completed a global meta‐analysis of any type of prostanoid given via any route versus placebo. The aim was to allow a meaningful meta‐analysis of the same class of drug with the same expected biochemical action. </p> <section id="CD006544-sec-0066"> <h5 class="title">Cardiovascular mortality</h5> <p>Three studies reported cardiovascular mortality (two on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>), and one on ciprostene (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>)), with a similar incidence in both groups (RR 0.81, 95% CI 0.41 to 1.58; 1170 participants; I² = 0%; <a href="./references#CD006544-fig-0006" title="">Analysis 1.1</a>). We used a fixed‐effect model because statistical heterogeneity was not important. </p> <p>Subgroup analysis by type of prostanoid revealed no differences for cardiovascular mortality (test for subgroup differences: Chi² = 0.54, df = 1 (P = 0.46), I² = 0%). </p> <p>The quality of this evidence is low given that all studies had high risk of attrition bias and the number of events in each group was small, resulting in a wide confidence interval that includes both appreciable benefit and harm (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD006544-sec-0067"> <h5 class="title">Total amputations</h5> <p>Twelve studies reported amputations: One study reported major, minor, and total amputations (<a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>); three reported major and minor amputations (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>); four reported major amputations (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>); and the remaining four reported the total number of amputations, including major and minor (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>). </p> <p>We pooled results for total (major and minor) amputations across the 12 studies (three on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), six on iloprost (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), one on taprostene (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>), one on lipo‐ecraprost (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>), and another on ciprostene (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>)). We found that 421/1572 events were reported in the prostanoids group and 337/1253 in the placebo group (RR 0.97, 95% CI 0.86 to 1.09; I² = 9%; <a href="./references#CD006544-fig-0007" title="">Analysis 1.2</a>). We used a fixed‐effect model owing to lack of important statistical heterogeneity. </p> <p>Subgroup analysis by type of prostanoid revealed differences for total amputations (test for subgroup differences: Chi² = 8.10, df = 4 (P = 0.09), I² = 50.6%) owing to better results with iloprost against placebo (RR 0.82, 95% CI 0.69 to 0.97) than with the other prostanoids, which showed minimal or no effect. </p> <p>Even though several trials were at high risk of attrition bias, when we performed a sensitivity analysis excluding those studies (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), effects of prostanoids with regards to the incidence of total amputations were not modified (RR 0.91, 95% CI 0.75 to 1.10; 1269 participants; I² = 0%; <a href="#CD006544-fig-0005">Figure 5</a>). For this reason, we consider the quality of this evidence to be high (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD006544-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Prostanoids versus placebo, outcome: 1.10 Total amputations. Sensitivity analysis excluding studies at high risk of attrition bias." data-id="CD006544-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Prostanoids versus placebo, outcome: 1.10 Total amputations. Sensitivity analysis excluding studies at high risk of attrition bias. </p> </div> </div> </div> </section> <section id="CD006544-sec-0068"> <h5 class="title">Quality of life</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD006544-sec-0069"> <h5 class="title">Adverse events</h5> <p>Fourteen studies reported adverse events. We excluded six studies from the meta‐analysis because they reported total numbers of adverse events instead of numbers of participants with at least one event (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0047" title="Efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease [A double‐blind, randomized, placebo‐controlled study to assess the efficacy and safety of CirculaseTM for the treatment of critical leg ischemia]. clinicaltrials.gov/ct2/show/NCT00059644. Date first received: 29 April 2003. ">NCT00059644</a>), or they reported tolerability outcomes entailing clinical heterogeneity in relation to the definition of adverse event (<a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>). </p> <p>Eight studies reported extractable information about numbers of participants with adverse events, and we included them in the meta‐analysis (four studies on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), one on PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>), and three on iloprost (<a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>)). Pooled results showed that 245/345 participants in the prostanoids group had adverse effects compared with 99/310 in the placebo group (RR 2.11, 95% CI 1.79 to 2.50; I² = 0%; <a href="./references#CD006544-fig-0008" title="">Analysis 1.3</a>). We used a fixed‐effect model because statistical heterogeneity was unimportant. </p> <p>Subgroup analysis by type of prostanoid revealed no differences for this outcome (test for subgroup differences: Chi² = 2.42, df = 2 (P = 0.30), I² = 17.4%). </p> <p>A sensitivity analysis excluding trials at high risk of selection bias did not affect the pooled estimate (RR 2.13, 95% CI 1.80 to 2.52; 600 participants; I² = 0%) (<a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>). Nevertheless, the quality of evidence regarding this outcome was moderate owing to high risk of attrition bias in six out of eight studies (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>); exclusion of these studies from the sensitivity analysis influenced the overall effect (RR 1.18, 95% CI 0.51 to 2.71; 81 participants; I² = 0%), resulting in a wider confidence interval that included both appreciable benefit and harm (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD006544-sec-0070"> <h5 class="title">Rest‐pain relief</h5> <p>We found 18 studies that reported rest‐pain relief. We excluded four studies from the meta‐analysis owing to unavailability of extractable or enough data for an appropriate analysis (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>). </p> <p>We included 10 studies in a fixed‐effect meta‐analysis for dichotomous assessment of rest‐pain relief (one on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>), two on PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>), six on iloprost (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>), and one on lipo‐ecraprost (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>)). As subgroup analysis revealed no differences between high‐dose and low‐dose iloprost against placebo for this outcome (test for subgroup differences: Chi² = 0.82, df = 1 (P = 0.37), I² = 0%) (RR 1.13, 95% CI 0.88 to 1.46; 739 participants; 10 studies; I² = 24%), we presented data from the two studies combined (<a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B)</a>. Pooled results indicate that 204/665 participants who received prostanoids and 117/514 who received placebo achieved rest‐pain relief (RR 1.30, 95% CI 1.06 to 1.59; I² = 18%; <a href="./references#CD006544-fig-0009" title="">Analysis 1.4</a>). Subgroup analysis revealed no differences between different types of prostanoids (test for subgroup differences: Chi² = 5.35, df = 3 (P = 0.15), I² = 43.9%). </p> <p>The quality of this evidence was moderate owing to high risk of attrition bias in five studies (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>). A sensitivity analysis excluding those studies (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>) yielded a similar incidence of rest‐pain relief in the group that received prostanoids compared with the group given placebo (RR 1.13, 95% CI 0.88 to 1.46; 739 participants; I² = 24%; <a href="./references#CD006544-fig-0010" title="">Analysis 1.5</a>). However, estimates lost precision and resulted in a wider confidence interval that included both appreciable benefit and harm. </p> <p>We included three studies with 984 participants in a meta‐analysis for continuous measurement of rest‐pain relief (two on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>) and one on PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>)). We summarised rest‐pain scores in a random‐effects model meta‐analysis for standardised mean differences (SMDs), obtaining 0.16 (95% CI ‐0.10 to 0.42; I² = 42%; <a href="./references#CD006544-fig-0011" title="">Analysis 1.6</a>). Confidence intervals of the prostanoids subgroups overlapped, and studies were too few to permit conclusions about whether one type of prostanoid produced more rest‐pain relief than another. The quality of this evidence is low owing to high risk of bias and inconsistency across included studies. </p> <p>Two other studies reported results regarding rest‐pain relief qualitatively, stating no significant differences between treatment and control groups (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>). </p> </section> <section id="CD006544-sec-0071"> <h5 class="title">Reduction in analgesic consumption</h5> <p>We found five studies that reported analgesics consumption. We excluded three studies from meta‐analysis: two because extractable data were unavailable (<a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>), and another because investigators reported a continuous outcome (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>). </p> <p>We included two studies in a fixed‐effect meta‐analysis for dichotomous assessment of reduction in analgesics consumption (one on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>), and one on iloprost (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>)). Pooled results showed that 47/64 participants receiving prostanoids and 38/71 receiving placebo achieved a reduction in analgesic consumption (RR 1.40, 95% CI 1.08 to 1.82; 135 participants; I² = 0%; <a href="./references#CD006544-fig-0012" title="">Analysis 1.7</a>). Subgroup analysis by type of prostanoid showed no differences for this outcome (test for subgroup differences: Chi² = 0.35, df = 1 (P = 0.56), I² = 0%). </p> <p><a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a> reported a significant reduction in mean daily analgesic consumption compared with baseline in both groups of participants, but the mean difference between groups was not statistically significant neither during the infusion (mean difference (MD) ‐0.20, 95% CI ‐1.06 to 0.66) nor after four days' follow‐up (MD 0.40, 95% CI ‐0.53 to 1.33). </p> <p>Two studies described results regarding analgesics consumption qualitatively, indicating no significant differences between treatment and control groups (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>). </p> <p>The quality of the evidence regarding this outcome is low owing to high risk of bias and imprecision, and a small number of events did not reach the optimal information size. </p> </section> <section id="CD006544-sec-0072"> <h5 class="title">Ulcer healing</h5> <p>We found 13 studies that reported ulcer healing. We excluded two studies from meta‐analysis: one because it included only diabetic patients with a significant proportion of neuropathic and microangiopathic ulcers and therefore represented a clinically different population from other studies (<a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>), and the other because investigators measured ulcer healing as a continuous outcome (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>). </p> <p>We included the remaining 11 studies in a random‐effects meta‐analysis (five studies on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), one on PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>), four on iloprost (<a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>), and another on ciprostene (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>)). As subgroup analysis revealed no differences between high‐dose and low‐dose iloprost against placebo for this outcome (test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.80), I² = 0%), we presented data from the two studies combined (<a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B)</a>. Pooled results show that 381/946 participants in the prostanoid group and 277/773 in the placebo group had some degree of ulcer healing (RR 1.24, 95% CI 1.04 to 1.48; 11 studies; I² = 39%; <a href="./references#CD006544-fig-0013" title="">Analysis 1.8</a>). Subgroup analysis by type of prostanoid revealed no differences for this outcome (test for subgroup differences: Chi² = 2.59, df = 3 (P = 0.46), I² = 0%). </p> <p>We performed sensitivity analysis excluding eight studies at high risk of attrition bias (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), which showed an influence on overall effect (RR 1.33, 95% CI 0.83 to 2.13; 478 participants; I² = 19%). Estimates lost precision, resulting in a wider confidence interval that included both appreciable benefit and harm. Therefore, the quality of this evidence is moderate (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a> reported that the group of participants receiving taprostene experienced no significant decrease in median ulcer size (161 to 177 mm²), whereas participants in the placebo group experienced an increase in median ulcer size (201 to 292 mm²) by the end of the infusion period. </p> </section> <section id="CD006544-sec-0073"> <h5 class="title">Major amputation</h5> <p>Eight studies reported major amputations (one on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>), five on iloprost (<a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), one on taprostene (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>), and one on lipo‐ecraprost (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>)). As subgroup analysis revealed no differences between high‐dose and low‐dose iloprost against placebo for this outcome (test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.93), I² = 0%), we presented data from the two studies combined (<a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B)</a>. </p> <p>A fixed‐effect meta‐analysis showed that 294/1373 participants in the prostanoid group and 247/1057 in the placebo group experienced this event (RR 0.84, 95% CI 0.73 to 0.98; I² = 0%; <a href="./references#CD006544-fig-0015" title="">Analysis 1.10</a>). Subgroup analysis by type of prostanoid revealed no differences for major amputations (test for subgroup differences: Chi² = 2.98, df = 3 (P = 0.40), I² = 0%). </p> <p>We conducted a sensitivity analysis excluding studies with high risk of attrition bias (<a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), thus diluting the beneficial effect of prostanoids for major amputations (RR 0.91, 95% CI 0.75 to 1.11; 1269 participants; I² = 0%). Therefore, the quality of evidence regarding this outcome is moderate. </p> </section> <section id="CD006544-sec-0074"> <h5 class="title">Minor amputation</h5> <p>Four studies reported the incidence of minor amputations (one on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>), two on iloprost (<a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), and another on taprostene (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>)). We observed this event in 81/485 participants in the prostanoid group and in 46/413 in the placebo group (RR 1.55, 95% CI 1.11 to 2.16; I² = 0%; <a href="./references#CD006544-fig-0016" title="">Analysis 1.11</a>). We used a fixed‐effect model owing to lack of important statistical heterogeneity. Subgroup analysis by type of prostanoid revealed no differences for minor amputations (test for subgroup differences: Chi² = 1.85, df = 2 (P = 0.40), I² = 0%). </p> <p>The quality of this evidence is low owing to high risk of attrition bias and imprecision. If we exclude studies at high risk of bias, only one study is left (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>). This study reported a similar incidence of minor amputations in those who received taprostene and those who received placebo (RR 0.87, 95% CI 0.27 to 2.80). </p> </section> <section id="CD006544-sec-0075"> <h5 class="title">Ankle brachial index</h5> <p>Two studies reported ankle brachial index (ABI) (one on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), and another on ciprostene (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>)). These studies presented data differently; therefore we could not perform a meta‐analysis. </p> <p><a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a> reported no significant improvement in ABI for both groups of participants at 24 hours (PGE<sub>1</sub> group, median 0.43, range 0 to 1.15; placebo group, median 0.50, range 0 to 1.0) or at one month after infusion (measurements of effect not reported). </p> <p><a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a> reported no differences for this outcome between participants who received ciprostene (average range 0.60 ± 0.038 to 0.67 ± 0.052) and those given placebo (0.60 ± 0.047 to 0.69 ± .047) during the study. </p> <p>The quality of this evidence is moderate owing to high risk of attrition bias.</p> </section> <section id="CD006544-sec-0076"> <h5 class="title">All‐cause mortality</h5> <p>Eleven studies reported all‐cause mortality (two on PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>), one on PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>), five on iloprost (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), one on taprostene (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>), one on lipo‐ecraprost (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>), and another on ciprostene (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>)). As subgroup analysis revealed no differences between high‐dose and low‐dose iloprost against placebo for this outcome (test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.89), I² = 0%), we presented data from the two studies combined (<a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B)</a>. </p> <p>Pooled results indicate a mortality incidence of 142/1548 in the prostanoid group and 95/1249 in the placebo group (RR 1.04, 95% CI 0.81 to 1.33; I² = 3%). Subgroup analysis by type of prostanoid revealed no differences for this outcome (test for subgroup differences: Chi² = 6.78, df = 5 (P = 0.24), I² = 26.3%). When excluding studies with high risk of attrition bias (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>), we noted no influence on the overall effect of prostanoids on all‐cause mortality (RR 1.06, 95% CI 0.78 to 1.43; 1297 participants; I² = 27%). However, owing to loss of precision and widening of the confidence interval, the quality of this evidence is moderate. </p> </section> </section> <section id="CD006544-sec-0077"> <h4 class="title">Prostanoids versus other active agents</h4> <p>Owing to the presence of significant clinical heterogeneity (types of experimental and control drugs differed significantly among included studies), we described results obtained upon various comparisons of prostanoids versus other active agents and performed meta‐analysis only for comparisons considering the same control intervention, when possible. </p> <section id="CD006544-sec-0078"> <h5 class="title">Prostanoids versus pentoxifylline</h5> <p>A single study with 70 participants compared intravenous infusion of PGE<sub>1</sub> versus pentoxifylline (<a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>). </p> <section id="CD006544-sec-0079"> <h6 class="title">Cardiovascular mortality</h6> <p>This study provided no information regarding this outcome.</p> </section> <section id="CD006544-sec-0080"> <h6 class="title">Total amputations</h6> <p>This trial reported a "borderline amputation" (an unclear type of amputation) in 1/35 participants who received PGE<sub>1</sub> and in 2/35 participants given pentoxifylline during the treatment phase (RR 0.50, 95% CI 0.05 to 5.27). The quality of this evidence is very low owing to high risk of bias and imprecision, with a small number of events not reaching the optimal information size (see <a href="./full#CD006544-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006544-sec-0081"> <h6 class="title">Quality of life</h6> <p>This included study did not report this outcome.</p> </section> <section id="CD006544-sec-0082"> <h6 class="title">Adverse events</h6> <p>Trial authors reported adverse events in 6/35 participants who received placebo and in 10/35 who received pentoxifylline (RR 0.60, 95% CI 0.24 to 1.47). Premature treatment discontinuation occurred only in 4/35 participants in the pentoxifylline group and in no participants in the PGE<sub>1</sub> group. The quality of this evidence is very low owing to high risk of bias and imprecision, with a small number of events not reaching the optimal information size (see <a href="./full#CD006544-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006544-sec-0083"> <h6 class="title">Rest<i>‐</i>pain relief and consumption of analgesics </h6> <p>Data show some degree of rest‐pain relief for 14/35 participants in the PGE<sub>1</sub> group and for 10/35 participants in the pentoxifylline group (RR 1.40, 95% CI 0.72 to 2.72), while in 16/35 participants in the PGE<sub>1</sub> group and for 14/35 participants in the pentoxifylline group, this symptom disappeared (RR 1.11, 95% CI 0.65 to 1.91) after four weeks' follow‐up. Data show no differences regarding consumption of analgesic drugs: 22/30 participants in the PGE<sub>1</sub> group and 17/29 in the pentoxifylline group reduced or discontinued consumption of analgesics by completion of treatment (RR 1.25, 95% CI 0.86 to 1.82). The quality of this evidence is very low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006544-sec-0084"> <h6 class="title">Ulcer healing</h6> <p>In the PGE<sub>1</sub> group, 29/35 participants experienced complete or partial ulcer healing according to a score system that included area, depth, floor, and edges of lesions as well as maintenance of a functioning extremity, compared with 18/35 participants in the pentoxifylline group who achieved this endpoint (RR 1.61, 95% CI 1.13 to 2.30). The quality of evidence provided by this randomised trial is very low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006544-sec-0085"> <h6 class="title">Major or minor amputations</h6> <p>This study reported the incidence of an unclear type of amputation, which we could not classify as major and could not classify as minor. </p> </section> <section id="CD006544-sec-0086"> <h6 class="title">Ankle brachial index</h6> <p>The included study did not report ABI as an outcome.</p> </section> <section id="CD006544-sec-0087"> <h6 class="title">All‐cause mortality</h6> <p>This included study did not report information regarding this outcome.</p> </section> </section> <section id="CD006544-sec-0088"> <h5 class="title">Prostanoids versus naftidrofuryl</h5> <p>Three studies with 75 participants compared a prostanoid with naftidrofuryl (one on intravenously administered PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>), another on intravenous PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>), and a third on intra‐arterial PGI<sub>2</sub> (<a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>)). </p> <section id="CD006544-sec-0089"> <h6 class="title">Cardiovascular mortality</h6> <p>None of these studies reported the incidence of cardiovascular mortality.</p> </section> <section id="CD006544-sec-0090"> <h6 class="title">Total amputations</h6> <p>A single study reported amputation events, which presented in 9/14 participants in the PGI<sub>2</sub> group and in 10/15 participants in the naftidrofuryl group (RR 0.96, 95% CI 0.57 to 1.64; <a href="./references#CD006544-fig-0018" title="">Analysis 2.1</a>) (<a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>). The quality of this evidence was low owing to high risk of attrition bias and imprecision issues. </p> </section> <section id="CD006544-sec-0091"> <h6 class="title">Quality of life</h6> <p>None of the included studies reported this outcome.</p> </section> <section id="CD006544-sec-0092"> <h6 class="title">Adverse events</h6> <p>We included two studies in a random‐effects meta‐analysis of adverse events (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>). We excluded <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a> from meta‐analysis because investigators stated numbers of adverse events in each group, instead of numbers of participants with at least one adverse event. We observed that 6/27 participants who received prostanoids and 1/28 who received naftidrofuryl presented adverse events during the infusion (RR 3.29, 95% CI 0.27 to 40.19; I² = 40%; <a href="./references#CD006544-fig-0019" title="">Analysis 2.2</a>). Subgroup analysis by type of prostanoid revealed no differences for this outcome (test for subgroup differences: Chi² = 1.56, df = 1 (P = 0.21), I² = 35.7%). The quality of evidence is low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD006544-sec-0093"> <h6 class="title">Rest‐pain relief and consumption of analgesics</h6> <p>The included studies reported rest‐pain relief as a dichotomous outcome, defined as any improvement in a pain scale at the end of treatment, which ranged between 3 and 21 days (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>). A fixed‐effect meta‐analysis showed that 24/37 participants who received prostanoids and 23/38 who received naftidrofuryl achieved some degree of rest‐pain relief (RR 1.07, 95% CI 0.83 to 1.39; I² = 22%; <a href="./references#CD006544-fig-0020" title="">Analysis 2.3</a>). Subgroup analysis by type of prostanoid revealed no differences for this outcome (test for subgroup differences: Chi² = 1.60, df = 2 (P = 0.45), I² = 0%). </p> <p>Sensitivity analysis excluding one study at high risk of selection bias (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>) showed no influence on overall effect (RR 1.28, 95% CI 0.77 to 2.13; 49 participants; I² = 0%). Similarly, neither a sensitivity analysis excluding two studies at high risk of performance and detection bias (open‐label trials) (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>), nor another excluding one study at high risk of attrition bias (<a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>), showed any influence on the estimated effect of prostanoids for this outcome (RR 1.31, 95% CI 0.80 to 2.15; and RR 0.93, 95% CI 0.75 to 1.14, respectively). Nevertheless, we consider the quality of this evidence as low owing to high risk of bias in critical domains for this subjective outcome and imprecision issues, including not reaching optimal information size (see <a href="./full#CD006544-tbl-0003">summary of findings Table 3</a>). </p> <p><a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a> reported that participants experiencing relief of rest‐pain reduced their consumption of analgesics (11/14 participants in PGI<sub>2</sub> group and 9/15 in naftidrofuryl group; RR 1.31, 95% CI 0.80 to 2.15). No other included studies reported this outcome. The quality of this evidence is low owing to high risk of attrition bias and imprecision issues. </p> </section> <section id="CD006544-sec-0094"> <h6 class="title">Ulcer healing</h6> <p>A meta‐analysis of two studies that reported evolution of tissue lesions showed that 7/18 participants receiving a prostanoid and 9/21 receiving naftidrofuryl experienced partial or complete ulcer healing (RR 0.97, 95% CI 0.46 to 2.03; I² = 0%; <a href="./references#CD006544-fig-0021" title="">Analysis 2.4</a>) (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>). Subgroup analysis by type of prostanoid revealed no differences for this outcome (test for subgroup differences: Chi² = 0.52, df = 1 (P = 0.47), I² = 0%). </p> <p>The quality of the evidence is very low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD006544-sec-0095"> <h6 class="title">Major or minor amputations</h6> <p>One study reported the incidence of minor amputations in 4/14 participants in the PGI<sub>2</sub> group and in 3/15 in the naftidrofuryl group (RR 1.43, 95% CI 0.39 to 5.28), with occurrence of major amputation in 5/14 participants in the PGI<sub>2</sub> group and in 7/15 in the naftidrofuryl group (RR 0.77, 95% CI 0.32 to 1.86) (<a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>). The quality of this evidence is low owing to high risk of attrition bias and the low rate of events not reaching the optimal information size. </p> </section> <section id="CD006544-sec-0096"> <h6 class="title">Ankle brachial index</h6> <p><a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a> reported pretreatment ABI stratified by severity of disease at long‐term follow‐up, with no mention of post‐treatment measurements for this outcome. No other included studies reported this outcome. </p> </section> <section id="CD006544-sec-0097"> <h6 class="title">All‐cause mortality</h6> <p>None of the included studies reported this outcome.</p> </section> </section> <section id="CD006544-sec-0098"> <h5 class="title">PGE<sub>1</sub> versus ATP </h5> <section id="CD006544-sec-0099"> <h6 class="title">Cardiovascular mortality</h6> <p>None of the included studies comparing PGE<sub>1</sub> and ATP reported the incidence of cardiovascular deaths. </p> </section> <section id="CD006544-sec-0100"> <h6 class="title">Total amputations</h6> <p>Two studies with 91 participants evaluated effects of PGE<sub>1</sub> compared with ATP (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>). Fixed‐effect meta‐analyses showed that 4/49 participants in the PGE<sub>1</sub> group underwent amputations compared with 13/42 in the ATP group (RR 0.26, 95% CI 0.09 to 0.74; I² = 0%; <a href="./references#CD006544-fig-0022" title="">Analysis 3.1</a>). The quality of this evidence is low owing to high risk of attrition bias and a low rate of events, resulting in a wide confidence interval (see <a href="./full#CD006544-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD006544-sec-0101"> <h6 class="title">Quality of life</h6> <p>None of the included studies comparing PGE<sub>1</sub> and ATP reported this outcome. </p> </section> <section id="CD006544-sec-0102"> <h6 class="title">Adverse events</h6> <p>Two studies with 91 participants evaluated effects of PGE<sub>1</sub> compared with ATP (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>). Fixed‐effect meta‐analyses showed that 26/49 participants in the PGE<sub>1</sub> group and 8/42 in the ATP group experienced adverse events (RR 2.78, 95% CI 1.41 to 5.48; I² = 14%; <a href="./references#CD006544-fig-0023" title="">Analysis 3.2</a>). The quality of this evidence is low owing to high risk of attrition bias and imprecision issues (see <a href="./full#CD006544-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD006544-sec-0103"> <h6 class="title">Rest‐pain relief</h6> <p>None of the included studies comparing PGE<sub>1</sub> and ATP reported rest‐pain relief as a dichotomous outcome. <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a> reported that both groups of participants experienced significant rest‐pain relief as a continuous outcome measured on a ten‐point analogue scale, changing from an initial mean of 6 to a mean of 3 at three weeks in the PGE<sub>1</sub> group, and from an initial mean of 6 to a mean of 3.5 in the ATP group at three weeks. This study did not provide standard deviation; therefore reanalysis was not possible. </p> <p><a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a> reported rest‐pain relief as part of a composite outcome along with consumption of analgesics and ulcer healing, and did not provide enough information to show how many participants experienced some degree of improvement for this outcome. </p> </section> <section id="CD006544-sec-0104"> <h6 class="title">Reduction in analgesics consumption</h6> <p><a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a> reported that consumption of analgesics was reduced or discontinued in 14/31 participants who received PGE<sub>1</sub> and in 10/26 who received ATP (RR 1.17, 95% CI 0.63 to 2.19). We considered the quality of this evidence as low owing to high risk of attrition bias and imprecision issues. </p> <p><a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a> reported this outcome as part of a composite outcome, along with rest‐pain relief and ulcer healing, not providing enough information to show how many participants experienced some degree of reduction in consumption of analgesics. </p> </section> <section id="CD006544-sec-0105"> <h6 class="title">Ulcer healing</h6> <p><a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a> reported that all participants in both groups experienced some degree of ulcer healing. Additionally, 3/18 in the PGE<sub>1</sub> group and 3/13 in the ATP group presented complete healing of trophic lesions (RR 0.72, 95% CI 0.17 to 3.03). We considered the quality of this evidence as low owing to high risk of attrition bias and imprecision issues (see <a href="./full#CD006544-tbl-0004">summary of findings Table 4</a>). </p> <p><a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a> reported healing of necrosis as a composite outcome, along with pain relief and consumption of analgesics, not providing enough information to indicate how many participants experienced ulcer healing as a separate outcome. </p> </section> <section id="CD006544-sec-0106"> <h6 class="title">Major or minor amputations</h6> <p>Information was insufficient to further classify amputation events reported by <a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a> and <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a> into major or minor amputations. </p> </section> <section id="CD006544-sec-0107"> <h6 class="title">Ankle brachial index</h6> <p>None of the included studies comparing PGE<sub>1</sub> and ATP reported this outcome. </p> </section> <section id="CD006544-sec-0108"> <h6 class="title">All‐cause mortality</h6> <p><a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a> reported that 1/18 participants in the PGE<sub>1</sub> group and 1/16 in the ATP group died during follow‐up (RR 0.89, 95% CI 0.06 to 13.08). The quality of this evidence is low owing to high risk of attrition bias and a low rate of events, resulting in a wide confidence interval. </p> </section> </section> <section id="CD006544-sec-0109"> <h5 class="title">PGE<sub>1</sub> versus inositol niacinate </h5> <p>A single study with 76 participants compared high‐dose (0.15 ng/kg/min) and low‐dose (0.05 ng/kg/min) intra‐arterial infusion of PGE<sub>1</sub> versus orally administered inositol niacinate (<a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>). </p> <section id="CD006544-sec-0110"> <h6 class="title">Cardiovascular mortality</h6> <p>The included study did not report this outcome.</p> </section> <section id="CD006544-sec-0111"> <h6 class="title">Total amputations</h6> <p><a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a> reported that most participants in the three groups that experienced no improvement in ulcer healing underwent surgical treatment, including amputation, and did not specify the incidence of these events. </p> </section> <section id="CD006544-sec-0112"> <h6 class="title">Quality of life</h6> <p>The included study did not report this outcome.</p> </section> <section id="CD006544-sec-0113"> <h6 class="title">Adverse events</h6> <p><a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a> reported adverse events in 16/22, 9/25, and 6/18 participants in high‐dose PGE<sub>1</sub>, low‐dose PGE<sub>1</sub> and inositol niacinate groups, respectively. As reanalysis of these data showed no statistical differences in the incidence of adverse events between high‐dose and low‐dose PGE<sub>1</sub> groups compared with inositol niacinate, we present data for the two PGE<sub>1</sub> groups combined (RR 1.60, 95% CI 0.79 to 3.23). The quality of this evidence is low owing to high risk of attrition bias and a low rate of events, resulting in a wide confidence interval (see <a href="./full#CD006544-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD006544-sec-0114"> <h6 class="title">Rest‐pain relief</h6> <p><a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a> reported that 18/22 participants who received high‐dose PGE<sub>1</sub>, 16/25 who received low‐dose PGE<sub>1</sub> and 9/18 given inositol niacinate experienced some degree of rest‐pain relief. As reanalysis of this data showed no statistical differences in the incidence of rest‐pain relief between high‐dose and low‐dose PGE<sub>1</sub> groups compared with inositol niacinate, we present data for the two PGE<sub>1</sub> groups combined (RR 1.45, 95% CI 0.88 to 2.37). The quality of this evidence is low owing to high risk of attrition bias and imprecision issues (see <a href="./full#CD006544-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD006544-sec-0115"> <h6 class="title">Reduction in analgesics consumption</h6> <p>The included study did not report this outcome.</p> </section> <section id="CD006544-sec-0116"> <h6 class="title">Ulcer healing</h6> <p><a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a> reported that 6/22 participants in the high‐dose PGE<sub>1</sub> group, 2/25 in the low‐dose PGE<sub>1</sub> group, and 1/18 in the inositol niacinate group achieved ulcer healing after treatment. Reanalysis of these data revealed no statistical differences in the incidence of this dichotomous outcome between high‐dose and low‐dose PGE<sub>1</sub> groups compared with inositol niacinate. For this reason, we present data for the two PGE<sub>1</sub> groups combined (RR 3.06, 95% CI 0.41 to 22.79). The quality of this evidence is low owing to high risk of attrition bias and imprecision issues resulting from a low rate of events (see <a href="./full#CD006544-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD006544-sec-0117"> <h6 class="title">Major or minor amputations</h6> <p>The included study did not report this outcome.</p> </section> <section id="CD006544-sec-0118"> <h6 class="title">Ankle‐brachial index</h6> <p>The included study did not report this outcome.</p> </section> <section id="CD006544-sec-0119"> <h6 class="title">All‐cause mortality</h6> <p><a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a> reported that one death was recorded in each group of participants within one year after completion of therapy. As reanalysis of these data showed no statistical differences in the incidence of this dichotomous outcome between high‐dose and low‐dose PGE<sub>1</sub> groups compared with inositol niacinate, we present data for the two PGE<sub>1</sub> groups combined (RR 0.77, 95% CI 0.07 to 7.94) .The quality of this evidence is low owing to high risk of attrition bias and imprecision issues. </p> </section> </section> </section> <section id="CD006544-sec-0120"> <h4 class="title">Prostanoids versus other prostanoids</h4> <p>Owing to the presence of significant clinical heterogeneity between the two comparisons among different prostanoids (study designs and route of administration differed significantly among included studies), we described results obtained from various comparisons of prostanoids versus other prostanoids. We performed meta‐analysis only for comparisons considering the same control intervention when more than one study reported the same outcome. </p> <section id="CD006544-sec-0121"> <h5 class="title">Iloprost versus PGE<sub>1</sub> </h5> <p>Four studies with 511 participants compared iloprost versus PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>). </p> <section id="CD006544-sec-0122"> <h6 class="title">Cardiovascular mortality</h6> <p>None of the included studies comparing iloprost versus PGE<sub>1</sub> reported the incidence of this event. </p> </section> <section id="CD006544-sec-0123"> <h6 class="title">Total amputations</h6> <p><a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a> reported that 44/106 participants in the iloprost group and 48/103 in the PGE<sub>1</sub> group underwent amputation procedures (RR 0.89, 95% CI 0.66 to 1.21). No other included studies comparing iloprost versus PGE<sub>1</sub> reported this outcome. The quality of this evidence is low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD006544-sec-0124"> <h6 class="title">Quality of life</h6> <p>None of the included studies comparing iloprost versus PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0125"> <h6 class="title">Adverse events</h6> <p>Four studies with 511 participants comparing iloprost versus PGE<sub>1</sub> reported this outcome (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>). Fixed‐effect meta‐analysis showed that 127/259 participants who received iloprost and 51/252 who received PGE<sub>1</sub> experienced adverse events (RR 2.35, 95% CI 1.82 to 3.04; I² = 0%; <a href="./references#CD006544-fig-0024" title="">Analysis 4.1</a>). Sensitivity analysis excluding studies with high risk of attrition bias revealed influence on the overall effect (RR 1.91, 95% CI 0.99 to 3.69; 172 participants; 2 studies; I² = 0%). The quality of this evidence is moderate owing to high risk of bias. </p> </section> <section id="CD006544-sec-0126"> <h6 class="title">Rest‐pain relief</h6> <p>A single study reported this outcome (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>), stating that 55/87 participants who received iloprost and 50/91 who received PGE<sub>1</sub> experienced some degree of pain relief (RR 1.15, 95% CI 0.90 to 1.47) by the end of treatment. The quality of this evidence is low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD006544-sec-0127"> <h6 class="title">Reduction in analgesics consumption</h6> <p>None of the included studies comparing iloprost versus PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0128"> <h6 class="title">Ulcer healing</h6> <p><a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a> reported that 60/112 participants in the iloprost group and 50/116 in the PGE<sub>1</sub> group achieved some degree of improvement or healing of trophic lesions (RR 1.24, 95% CI 0.95 to 1.63) by the end of treatment. No other included studies comparing iloprost versus PGE<sub>1</sub> reported this outcome.The quality of this evidence is low owing to high risk of bias and imprecision issues (see <a href="./full#CD006544-tbl-0006">summary of findings Table 6</a>). </p> </section> <section id="CD006544-sec-0129"> <h6 class="title">Major or minor amputations</h6> <p><a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a> reported that minor amputations were performed in 19/106 participants receiving iloprost and in 19/103 receiving PGE<sub>1</sub> (RR 0.97, 95% CI 0.55 to 1.73), and 34/106 participants in the iloprost group and 28/103 in the PGE<sub>1</sub> group had major amputations (RR 1.18, 95% CI 0.78 to 1.80) after six months' follow‐up. No other included studies comparing iloprost versus PGE<sub>1</sub> reported amputation events. We consider this evidence as low quality owing to high risk of bias and imprecision issues. </p> </section> <section id="CD006544-sec-0130"> <h6 class="title">Ankle brachial index</h6> <p>None of the included studies comparing iloprost versus PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0131"> <h6 class="title">All‐cause mortality</h6> <p>A single study reported this outcome (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>). Death occurred in 8/106 participants in the iloprost group and in 15/103 in the PGE<sub>1</sub> group (RR 0.52, 95% CI 0.23 to 1.17) by six months' follow‐up. The quality of this evidence is low owing to high risk of attrition bias and a low rate of events, resulting in a wide confidence interval. </p> </section> </section> <section id="CD006544-sec-0132"> <h5 class="title">Clinprost versus lipo‐PGE<sub>1</sub> </h5> <p>A single study with 135 participants compared clinprost incorporated in lipid microspheres versus lipo‐PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>). We present results for the subgroup of 72 participants with CLI of atherosclerotic origin, excluding those for the subgroup with a diagnosis of thromboangiitis obliterans (TAO; 63 participants). For the outcomes "cardiovascular mortality", "adverse events", and "total mortality", we could not retrieve disaggregated data. </p> <section id="CD006544-sec-0133"> <h6 class="title">Cardiovascular mortality</h6> <p>Authors of the single study included for this comparison mentioned the incidence of one death due to acute heart failure in the clinprost group during the trial (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>). This report does not specify whether this happened in the CLI of atherosclerotic origin group or in the TAO group. </p> </section> <section id="CD006544-sec-0134"> <h6 class="title">Total amputations</h6> <p>None of the included studies comparing clinprost versus lipo‐PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0135"> <h6 class="title">Quality of life</h6> <p>None of the included studies comparing clinprost versus lipo‐PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0136"> <h6 class="title">Adverse events</h6> <p>This study reported an incidence of adverse events of 7/66 participants in the clinprost group and 4/69 in the lipo‐PGE<sub>1</sub> group (RR 1.83, 96% CI 0.56 to 5.96), although trial authors did not report adverse events separately for participants with PAOD or TAO. The quality of this evidence is moderate owing to imprecision issues because events were few, resulting in a wide confidence interval that included both harms and benefits (see <a href="./full#CD006544-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD006544-sec-0137"> <h6 class="title">Rest‐pain relief</h6> <p><a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a> reported that 14/34 participants in the clinprost group and 13/33 in the lipo‐PGE<sub>1</sub> group achieved some degree of rest‐pain relief (RR 1.05, 95% CI 0.58 to 1.87). The quality of this evidence is low owing to high risk of attrition bias and imprecision due to a small number of events (see <a href="./full#CD006544-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD006544-sec-0138"> <h6 class="title">Reduction in analgesics consumption</h6> <p>None of the included studies comparing clinprost versus lipo‐PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0139"> <h6 class="title">Ulcer healing</h6> <p><a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a> stated that 20/37 participants in the clinprost group and 16/35 in the lipo‐PGE<sub>1</sub> group achieved some degree of ulcer healing (RR 1.18, 95% CI 0.74 to 1.89). The quality of this evidence is low owing to high risk of attrition bias and imprecision due to a small number of events (see <a href="./full#CD006544-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD006544-sec-0140"> <h6 class="title">Major or minor amputations</h6> <p>None of the included studies comparing clinprost versus lipo‐PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0141"> <h6 class="title">Ankle brachial index</h6> <p>None of the included studies comparing clinprost versus lipo‐PGE<sub>1</sub> reported this outcome. </p> </section> <section id="CD006544-sec-0142"> <h6 class="title">All‐cause mortality</h6> <p>As mentioned above for "cardiovascular mortality", authors of the single study included for this comparison mentioned the incidence of one death due to acute heart failure in the clinprost group during the trial (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>). This report does not specify whether this happened in the CLI of atherosclerotic origin group or in the TAO group. </p> </section> </section> </section> <section id="CD006544-sec-0143"> <h4 class="title">Adverse events analysed by type of prostanoid</h4> <section id="CD006544-sec-0144"> <h5 class="title">PGE<sub>1</sub> </h5> <p>PGE<sub>1</sub> was the experimental intervention in 16 studies: seven versus placebo (<a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0020" title="JogestrandT , OlssonAG . The effect of intravenous prostaglandin E1 on ischaemic pain and on leg blood‐flow in subjects with peripheral artery disease: a double‐blind controlled study. Clinical Physiology (Oxford, England)1985; Vol. 5, issue 6:495‐502. [CN‐00041639] ">Jogestrand 1985</a>; <a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>), four versus iloprost (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>), one versus pentoxifylline (<a href="./references#CD006544-bbs2-0033" title="TrubesteinG , VonBaryS , BreddinK , DiehmC , GrussJD , HeinrichH , et al. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease ‐ a controlled randomised multicenter study. VASA Supplementum1989;28:44‐9. ">Trübestein 1989</a>), two versus ATP (<a href="./references#CD006544-bbs2-0006" title="BöhmeH , BrulisauerM , HartelU , BollingerA . Peripheral arterial occlusive disease stage III and IV. Medizinische Welt1989;40(51‐52):1501‐3. ">Böhme 1989</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>), one versus naftidrofuryl (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>), and another versus inositol niacinate (<a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>). One study compared lipo‐PGE<sub>1</sub>, a preparation of PGE<sub>1</sub> incorporated in lipid microspheres, versus clinprost (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>). </p> <p>Taken together, participants treated with a prostanoid reported the following as the most common adverse events: phlebitis, thrombophlebitis or pain at the infusion site or both, headache, nausea, flushing, and hypotension. During intra‐arterial infusion, few participants presented swelling, dull pain, redness, and/or fever (<a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>; <a href="./references#CD006544-bbs2-0032" title="TrubesteinG , DiehmC , GrussJD , HorschS . Prostaglandin E1 in chronic arterial disease ‐ a multicenter study. VASA Supplementum1987;17:39‐43. [PUBMED: 3470965] TrubesteinG , LudwigM , DiehmC , GrussJD , HorschS . Prostaglandin E1 in stage III and IV arterial occlusive disease: results of a multi‐center trial. Deutsche Medizinische Wochenschrift1987;112(24):955‐9. ">Trubestein 1987</a>). Cardiovascular events, such as atrial fibrillation, chest pain, dyspnoea, and severe changes in blood pressure, were occasionally reported (<a href="./references#CD006544-bbs2-0023" title="Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (ESPECIAL) [Multinational, prospective, randomized, double blind, placebo controlled, parallel groups study to assess the efficacy and safety of prostaglandin E1 in subjects with critical limb ischemia (Fontaine Stage IV)]. clinicaltrials.gov/ct2/show/NCT00596752. Date first received: 21 December 2007. [2005‐001970‐29 ( EudraCT Number); SP0777 (Sponsor ID)] ">NCT00596752</a>; <a href="./references#CD006544-bbs2-0026" title="ReisinL , MarmorA , RabinowitzB , BerninkPJ , CaspiA , RuzylloW , et al. Safety of prostaglandin E1 for the treatment of peripheral arterial occlusive disease in patients with congestive heart failure. American Journal of Therapeutics1997; Vol. 4, issue 11‐12:365‐74. [CN‐00265681] ">Reisin 1997</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0030" title="StieglerH , DiehmC , GromE , MartinM , MorlH , RudofskyG , et al. Placebo controlled, double‐blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease [Placebokontrollierte, doppelblinde Studie zur Wirksamkeit von i.v. Prostaglandin E1 bei Diabetikern mit AVK im Stadium IV]. VASA1992;35 (Suppl):164‐6. ">Stiegler 1992</a>). Five studies stated that symptoms improved with a decrease in infusion rate (<a href="./references#CD006544-bbs2-0007" title="BöhmeH , HartelU , WalterH . Naftidrofuryl in comparison to alprostadil in peripheral arterial occlusive disease stage III and IV. Medizinische Welt1994;45(5):209‐13. ">Böhme 1994</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>; <a href="./references#CD006544-bbs2-0027" title="SakaguchiS . Prostaglandin E1 intra‐arterial infusion therapy in patients with ischemic ulcer of the extremities. International Angiology1084;3:39‐41. ">Sakaguchi 1984</a>; <a href="./references#CD006544-bbs2-0029" title="RhodesRS , HeardSE . Detrimental effect of high‐dose prostaglandin Esub 1 in the treatment of ischemic ulcers. Surgery1983; Vol. 93, issue 6:839‐42. [CN‐00177644] SchulerJJ , FlaniganDP , HolcroftJW , UrsprungJJ , MohrlandJS , PykeJ . Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double‐blind, multicenter clinical trial. Journal of Vascular Surgery1984;1(1):160‐70. [PUBMED: 6384558] ">Schuler 1984</a>; <a href="./references#CD006544-bbs2-0031" title="TellesGS , CampbellWB , WoodRFM , CollinJ , BairdRN , MorrisPJ , et al. Prostaglandin E1 in severe lower limb ischaemia: a double‐blind controlled trial. British Journal of Surgery1984;71(7):506‐8. ">Telles 1984</a>). </p> </section> <section id="CD006544-sec-0145"> <h5 class="title">PGI<sub>2</sub> </h5> <p>Even though PGI<sub>2</sub> was the experimental drug in five studies (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>; <a href="./references#CD006544-bbs2-0019" title="HossmannV , AuelH , RuckerW , SchrorK . Long‐term infusion of epoprostenol (prostacyclin) in patients with occlusive arteriopathy stage III‐IV. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin1983;89:540‐4. ">Hossmann 1983</a>; <a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>; <a href="./references#CD006544-bbs2-0024" title="NegusD , IrvingJD , FriedgoodA . Intra‐arterial prostacyclin compared to praxilene in the management of severe lower limb ischaemia: a double blind trial. Journal of Cardiovascular Surgery (Torino)1987;28(2):196‐9. ">Negus 1987</a>), only three of them reported adverse events: two versus placebo (<a href="./references#CD006544-bbs2-0004" title="BelchJJ , McKayA , McArdleB , LeibermanP , PollockJG , LoweGD , et al. Epoprostenol (prostacyclin) and severe arterial disease. A double‐blind trial. Lancet1983;1(8320):315‐7. ">Belch 1983</a>; <a href="./references#CD006544-bbs2-0011" title="CronenwettJL , ZelenockGB , WhitehouseWMJr , LindenauerSM , GrahamLM , StanleyJC . Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease. Surgery1986;100(2):369‐75. ">Cronenwett 1986</a>), and one versus naftidrofuryl (<a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>). The most commonly reported adverse events were flushing, headache, nausea and vomiting, painful skin inflammation, diarrhoea, and hypotension. One patient presented exanthema (<a href="./references#CD006544-bbs2-0021" title="KarnikR , ValentinA , SlanyJ . A randomized study on patients with peripheral arterial occlusive disease (PAOD) stage III and IV. Herz Kreislauf1986;18(12):644‐7. ">Karnik 1986</a>). </p> </section> <section id="CD006544-sec-0146"> <h5 class="title">Iloprost</h5> <p>Iloprost was the experimental intervention in 12 studies: 11 versus placebo (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>), and one versus PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0028" title="SchellongS , AltmannE , vonBilderlingP , RudofskyG , WaldhausenP , RogattiW . Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross‐over study in patients with critical limb ischemia. Prostaglandins Leukotrienes and Essential Fatty Acids2004;70(6):503‐9. ">Schellong 2004</a>). </p> <p>The most commonly reported adverse events were headache, nausea, and flushing (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>). Two studies reported phlebitis or adverse reaction at the injection site, or both (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>). Seven studies reported abdominal pain, diarrhoea, vomiting, and diaphoresis (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>). Participants in eight studies presented changes in blood pressure ‐ both severe hypotension and hypertension (<a href="./references#CD006544-bbs2-0001" title="AltstaedtHO , BerzewskiB , BreddinHK , BrockhausW , BruhnHD , CachovanM , et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukotrienes Essential Fatty Acids1993;49(2):573‐8. ">Alstaedt 1993</a>; <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>). Four studies alluded to cardiac adverse events, such as arrhythmia, chest pain, pulmonary oedema, and myocardial infarction, among sporadic participants in four studies (<a href="./references#CD006544-bbs2-0002" title="BalzerK , BecharaG , BislerH , ClevertHD , DiehmC , HeisigG , et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. International Angiology1991;10(4):229‐32. ">Balzer 1991</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>). One study reported an altered state of consciousness (confusion) (<a href="./references#CD006544-bbs2-0010" title="CastagnoPL , MolfettaL , MerloM , BarileG , ViolatoF , BuzzacchinoA , et al. Prospects of prostanoid therapy. Preliminary results. Minerva Cardioangiologica2000; Vol. 48, issue 1‐2:9‐18. [CN‐00278141] ">Castagno 2000</a>), another reported a vasovagal syncope (<a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>), and two studies reported that two stroke events occurred in the treatment group (<a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0025" title="NorgrenL , AlwmarkA , AngqvistKA , HedbergB , BergqvistD , TakolanderR , et al. A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb. European Journal of Vascular Surgery1990;4(5):463‐7. ">Norgren 1990</a>). </p> <p>In most cases, trial authors reported that symptoms were ameliorated when infusion speed was decreased (<a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>; <a href="./references#CD006544-bbs2-0009" title="BrockFE , AbriO , BaitschG , BecharaG , BeckK , CorovicD , et al. Iloprost in the treatment of ischemic tissue lesions in diabetics: results of a placebo‐controlled multicenter study with a stable prostacyclin derivative. Schweizerische Medizinische Wochenschrift1990;120(40):1477‐82. ">Brock 1990</a>; <a href="./references#CD006544-bbs2-0013" title="DiehmC , AbriO , BaitschG , BecharaG , BeckK , BreddinHK , et al. Iloprost, a stable prostacyclin derivative, in stage IV arterial disease. A placebo‐controlled multicentre study. Deutsche Medizinische Wochenschrift1989;114(20):783‐8. ">Diehm 1989</a>; <a href="./references#CD006544-bbs2-0014" title="DormandyJA , U.K. Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double‐blind placebo controlled study. European Journal of Vascular Surgery1991;5(5):511‐6. ">Dormandy 1991</a>; <a href="./references#CD006544-bbs2-0015" title="DormandyJ , BelcherG , BoccalonH , BragaA , BreddinK , CatalanoM , et al. Controlled randomized study of an oral prostacyclin analogue (iloprost) in patients with inoperable stage III and IV leg ischaemia. British Journal of Surgery1996;83(4):558‐9. DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study A. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000a ‐ Study A</a>; <a href="./references#CD006544-bbs2-0016" title="DormandyJA . Two randomised and placebo‐controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. Study B. European Journal of Vascular and Endovascular Surgery2000;20(4):358‐62. ">Dormandy 2000b ‐ Study B</a>; <a href="./references#CD006544-bbs2-0018" title="GuilmotJ‐L , DiotE , French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analogue of prostacyclin. Results of a French Multicentre Trial. Drug Investigation1991;3(5):351‐9. ">Guilmot 1991</a>). </p> </section> <section id="CD006544-sec-0147"> <h5 class="title">Taprostene</h5> <p>One study compared the experimental drug taprostene versus placebo (<a href="./references#CD006544-bbs2-0005" title="BelchJJ , RayS , Rajput‐RayM , EngesetJ , FagrellB , LepantaloM , et al. The Scottish‐Finnish‐Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia. International Angiology2011;30(2):150‐5. [PUBMED: 21427652] ">Belch 2011</a>). Trial authors described flushing and headache as the most common adverse events. </p> </section> <section id="CD006544-sec-0148"> <h5 class="title">Ciprostene</h5> <p>A single study provided ciprostene as the experimental intervention versus placebo (<a href="./references#CD006544-bbs2-0022" title="LinetOI , EckertSM , HuangDC . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. Journal of Clinical Pharmacology1991;31(1):81‐7. ">Linet 1991</a>). Trial authors reported that the most common adverse events were headache, nausea, and flushing. Hypotension, vomiting, jaw pain, and restlessness were less common. Five participants in the treatment group died as the result of heart failure, myocardial infarction, cardiac arrest, chronic obstructive pulmonary disease, and sepsis, respectively. </p> </section> <section id="CD006544-sec-0149"> <h5 class="title">Lipo‐ecraprost</h5> <p>Lipo‐ecraprost was the experimental drug in one study (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>). Commonly reported adverse reactions secondary to infusion were headache, pain, hypotension, tachycardia, vasodilation, diarrhoea, nausea, and vomiting. Investigators also reported 11 cases of congestive heart failure and 14 myocardial infarctions. </p> </section> <section id="CD006544-sec-0150"> <h5 class="title">Clinprost</h5> <p>One single study provided clinprost incorporated in lipid microspheres as the experimental intervention for comparison with lipo‐PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0017" title="EsatoK , YasudaK , AbeT , HoshinoS , IshimaruS , HoriG , et al. Studies on the clinical efficacy and safety of TTC‐909 in the treatment of peripheral arterial occlusive disease: a multi‐center double‐blind comparison with Alprostadil incorporated in lipid microspheres [TTC‐909の慢性動脈閉塞症に対する臨床的有効性と安全性の検討 Alprostadil含有脂肪乳剤を対照薬とした多施設二重盲検群間比較試験]. Rinsho Iyaku1995; Vol. 11, issue 10:2111‐41. [CN‐00543666] ">Esato 1995</a>). Adverse events described in the clinprost group included nausea, anorexia, diarrhoea, dizziness, liver disorder, tinnitus, and frizzy hair, although trial authors did not report adverse events separately for participants with PAOD or thromboangitis obliterans. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006544-sec-0151" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006544-sec-0151"></div> <section id="CD006544-sec-0152"> <h3 class="title" id="CD006544-sec-0152">Summary of main results</h3> <p>We updated this systematic review including 33 studies that evaluated the effects and safety of prostanoids, a family of drugs proposed to increase blood supply, for patients with critical limb ischaemia, a severe arterial obstruction affecting the lower limbs that causes rest‐pain and necrosis of soft tissues, who are unable to receive any revascularisation procedure. </p> <section id="CD006544-sec-0153"> <h4 class="title">Prostanoids versus placebo</h4> <p>Moderate‐quality evidence shows small effects of prostanoids (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>) in terms of rest‐pain relief, reduction of analgesics consumption, and ulcer healing compared with placebo. However, high‐quality evidence shows no effect on the incidence of total amputations. Nevertheless, subgroup analysis revealed a small reduction in the incidence of total amputations for iloprost. Regarding major and minor amputations, effects derived from moderate‐quality evidence showed opposite directions ‐ favouring prostanoids for major amputations, but favouring placebo for minor amputations. Selective outcome reporting across studies could have affected the direction of these results. Moderate‐quality evidence shows no differences in all‐cause mortality between placebo and prostanoids groups. Low‐quality evidence suggests no differences in cardiovascular mortality between placebo and prostanoid groups. None of the included studies reported measurements of quality of life. The incidence of adverse effects was consistently greater in those treated with prostanoids. The most frequently reported adverse events were headache, nausea, vomiting, diarrhoea, flushing, and hypotension. </p> <p>Results from the meta‐analysis were not statistically heterogeneous. However, they should be appraised with caution because of the presence of clinical heterogeneity and the potential influence of bias. Effects of prostanoids on rest‐pain relief, major amputations, and adverse events were diluted with exclusion of studies at high risk of bias. All‐cause mortality and total amputations were not affected by the sensitivity analysis. </p> </section> <section id="CD006544-sec-0154"> <h4 class="title">Prostanoids versus other agents</h4> <p>A single study comparing a prostanoid (prostaglandin E<sub>1</sub> (PGE<sub>1</sub>)) versus pentoxifylline found no clear differences in effects on amputation, rest‐pain relief, reduction in analgesic consumption, or adverse events, although more participants who received PGE<sub>1</sub> achieved some degree of ulcer healing (very low‐quality evidence; see <a href="./full#CD006544-tbl-0002">summary of findings Table 2</a>). When compared with naftidrofuryl (see <a href="./full#CD006544-tbl-0003">summary of findings Table 3</a>), prostanoids had no significant effect on rest‐pain relief, ulcer healing, amputations, or adverse events (low‐quality evidence). In two studies comparing PGE<sub>1</sub> versus adenosine triphosphate (ATP) (see <a href="./full#CD006544-tbl-0004">summary of findings Table 4</a>), PGE<sub>1</sub> had a significant effect on reduction of total amputations, with an increased incidence of adverse events; the remaining outcome measures were not combined owing to different definitions for each study, but study authors separately reported no differences regarding the incidence of rest‐pain relief, reduction in consumption of analgesics, or ulcer healing (low‐quality evidence). A single study compared intra‐arterial PGE<sub>1</sub> versus oral inositol niacinate, reporting no differences in the incidence of rest‐pain relief, reduction in consumption of analgesics, or ulcer healing (low‐quality evidence; see <a href="./full#CD006544-tbl-0005">summary of findings Table 5</a>). Studies comparing prostanoids versus other agents did not report cardiovascular mortality or quality of life. </p> </section> <section id="CD006544-sec-0155"> <h4 class="title">Head‐to‐head comparisons between prostanoids</h4> <p>We found two comparisons of different prostanoids: iloprost versus PGE<sub>1</sub>, and clinprost incorporated in lipid microspheres versus lipo‐PGE<sub>1</sub>. Participants treated with iloprost had a greater incidence of adverse events compared with those given PGE<sub>1</sub> (moderate‐quality evidence; see <a href="./full#CD006544-tbl-0006">summary of findings Table 6</a>). A single study reported no differences in the incidence of amputations, mortality, rest‐pain relief, and ulcer healing for the same comparison. Data show no differences for ulcer healing or rest‐pain relief in the subgroup of participants with peripheral arterial occlusive disease (PAOD)/critical limb ischaemia as reported by a single study on clinprost compared with lipo‐PGE<sub>1</sub> (low‐quality evidence; see <a href="./full#CD006544-tbl-0007">summary of findings Table 7</a>). </p> </section> </section> <section id="CD006544-sec-0156"> <h3 class="title" id="CD006544-sec-0156">Overall completeness and applicability of evidence</h3> <p>The relevance of evidence gathered for this update on the efficacy of prostanoids for patients with CLI is uncertain for several reasons. Even though most of the included studies described consistent selection criteria used for the study population, the concept of critical limb ischaemia without a chance of rescue or reconstructive intervention is a subjective definition. Thus, the diagnosis for a particular participant could have varied across studies according to centre characteristics, availability of endovascular procedures, and physician judgement. Most included studies recruited participants from countries in Europe, and this could limit transferability of results to other populations. Moreover, given that most identified studies were developed during the 1980s and 1990s, and that during past decades, both standard of care for patients with chronic PAOD and endovascular technologies for revascularisation have significantly improved (<a href="./references#CD006544-bbs2-0099" title="TeraaM , ConteMS , MollFL , VerhaarMC . Critical limb ischemia: current trends and future directions. Journal of the American Heart Association2016;5(2):e002938. ">Teraa 2016</a>), we have reason to believe that a higher degree of severity of disease is currently needed if a patient will be considered as having no chance of reconstructive intervention. </p> <p>Given the chronic nature of the condition of patients with CLI, and that most included studies provided short‐term results (one to six months), we could not provide conclusions regarding long‐term (&gt; 1 year) efficacy and safety of prostanoids. Similarly, owing to different doses and routes of administration used by primary studies, and even though we performed subgroup analysis by type of prostanoid, we are unable to determine which was the optimal posology. Additionally, none of the included randomised controlled trials (RCTs) assessed the variable quality of life, which we consider to be a very important patient‐centred outcome. </p> </section> <section id="CD006544-sec-0157"> <h3 class="title" id="CD006544-sec-0157">Quality of the evidence</h3> <p>For this update, we included 33 RCTs with a total of 4477 participants. We present assessment of the risk of bias in <a href="#CD006544-fig-0002">Figure 2</a> and <a href="#CD006544-fig-0003">Figure 3</a>. When considering selection bias, we noted that 27/33 and 26/33 studies had unclear risk of bias for random sequence generation and allocation concealment, respectively. Only 6/33 and 5/33 had low risk of bias for the aforementioned domains. Most studies (21/33) had low risk of performance bias, and 5/33 and 7/33 had uncertain and high risk of bias, respectively, for this domain. We rated 10/33 studies as having low risk of detection bias, and 16/33 and 7/33 as having unclear and high risk of detection bias, respectively. Finally, regarding incomplete outcome data, 21/33 studies had high risk of bias, and only 8/33 and 16/33 studies had low and unclear risk of bias, respectively. Attrition bias was a significant contributor to downgrading of the body of evidence for most outcomes. </p> <p>For the comparison prostanoids versus placebo (see <a href="./full#CD006544-tbl-0001">summary of findings Table for the main comparison</a>), the overall quality of evidence for most outcomes was moderate owing to high risk of attrition bias. Overall beneficial effects of prostanoids on the incidence of major amputations, ulcer healing, and pain relief were diluted with exclusion of studies with high risk of attrition bias. The same phenomenon was evident with the incidence of adverse events. Attrition bias did not influence overall effects of prostanoids on amputation while precision is maintained; therefore, we rated the quality of the evidence as high. Attrition bias did not influence overall effects of prostanoids on mortality and cardiovascular mortality. In this case, however, precision was affected; therefore, the quality of the evidence was low. </p> <p>Unfortunately we could not perform sensitivity analysis for all outcomes and comparisons because in some cases, all studies included in the meta‐analysis had high risk of bias, and we therefore could not assess the influence of bias on these outcomes (cardiovascular mortality, rest‐pain relief as a continuous outcome, and reduction in analgesic consumption with prostanoids vs placebo; pain relief, ulcer healing, and adverse events with prostanoids vs naftidrofuryl; total amputations and adverse events with PGE<sub>1</sub> vs ATP; and adverse events with iloprost vs PGE<sub>1</sub>). </p> <p>For comparisons of prostanoids versus other agents (see <a href="./full#CD006544-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD006544-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD006544-tbl-0004">summary of findings Table 4</a>; and <a href="./full#CD006544-tbl-0005">summary of findings Table 5</a>), we included studies at high risk of bias that had a low incidence of events and a small sample size. Therefore we rated the quality of evidence as low or very low owing to imprecision and high risk of bias. </p> <p>For comparisons between prostanoids (see <a href="./full#CD006544-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD006544-tbl-0007">summary of findings Table 7</a>), we also included studies at high risk of bias that had a low incidence of events and a small sample size. Therefore we rated the quality of evidence as low or very low owing to imprecision and high risk of bias. </p> </section> <section id="CD006544-sec-0158"> <h3 class="title" id="CD006544-sec-0158">Potential biases in the review process</h3> <p>As described in the <a href="#CD006544-sec-0057">Excluded studies</a> section, for this update we reclassified excluded studies from the original review as the result of changes in exclusion criteria regarding the quality of studies. We preferred this approach to minimising selection bias in the review process. Nevertheless, we had to exclude four studies owing to inability to retrieve a full text, and seven studies because they did not provide disaggregated data for the population of interest. Additionally, even though statistical analysis and funnel plot representation (<a href="#CD006544-fig-0004">Figure 4</a>) did not introduce suspicion of publication bias, we were unable to find the larger trial mentioned by <a href="./references#CD006544-bbs2-0003" title="BandieraG , DiCrisciD , CamilliS . Analysis of side effects of prostanoid‐based treatment in patients suffering from critical ischaemia of the lower limbs. Chronica Dermatologica1995;5(2):249‐60. ">Bandiera 1995</a>, and we could find neither published nor unpublished data from the study <a href="./references#CD006544-bbs2-0047" title="Efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease [A double‐blind, randomized, placebo‐controlled study to assess the efficacy and safety of CirculaseTM for the treatment of critical leg ischemia]. clinicaltrials.gov/ct2/show/NCT00059644. Date first received: 29 April 2003. ">NCT00059644</a>.<br/> <br/> Selective or inadequate outcome reporting was frequent, and only two trial authors replied when we attempted to contact them to obtain clarification (<a href="./references#CD006544-bbs2-0008" title="BrassEP , AnthonyR , DormandyJ , HiattWR , JiaoJ , NakanishiA , et al. (Circulase investigators). Parenteral therapy with lipo‐ecraprost, a lipid‐based formulation of a PGE1 analog, does not alter six‐month outcomes in patients with critical leg ischemia. Journal of Vascular Surgery2006;43(4):752‐9. ">Brass 2006</a>; <a href="./references#CD006544-bbs2-0012" title="DiehmC , Hubsch‐MullerC , StammlerF . Intravenous prostaglandin E1 therapy in patients with stage III peripheral arterial disease ‐ a double‐blind placebo controlled study. Prostaglandin E1 Wirkungen und Therapeutische Wirksamkeit. Berlin/Heidelberg/New York: Springer, 1988:133‐43. DiehmC , StammlerF , HubschC , WilhelmC , EcksteinHH . Treatment of rest pain in peripheral arterial occlusive disease (PVVK) with intravenous prostaglandin infusion. Vasa Supplementum1987;20:204‐5. DiehmC , StammlerF , Hubsch‐MullerC , EcksteinHH , SiminiB . Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD) ‐ a preliminary report on a placebo‐controlled double‐blind study. Vasa Supplementum1987;17:52‐6. ">Diehm 1988</a>). In most cases, author contact information was neither available nor current (many studies were reported in the 1980s). We tried to obtain new contact information (email addresses), but most attempts were unsuccessful.<br/> Assumptions made when meta‐analysis was conducted are a potential source of bias. For rest‐pain relief and ulcer healing, we did not restrict the definition of improvement at any specific cut‐off point. Minimal and non‐clinically relevant improvements in pain and ulcer healing could lead to overestimation of effects. Additionally, even though most meta‐analyses had low statistical heterogeneity, for these outcomes most studies included heterogeneous measurements or non‐validated scales/scores. </p> </section> <section id="CD006544-sec-0159"> <h3 class="title" id="CD006544-sec-0159">Agreements and disagreements with other studies or reviews</h3> <p>Some published meta‐analyses stated the beneficial effects of iloprost (<a href="./references#CD006544-bbs2-0082" title="LoosemoreTM , ChalmersTC , DormandyJA . A meta‐analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. International Angiology1994;13(2):133‐42. ">Loosemore 1994</a>), PGE<sub>1</sub> (<a href="./references#CD006544-bbs2-0063" title="CreutzigA , LehmacherW , ElzeM . Meta‐analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa2004;33(3):137‐44. ">Creutzig 2004</a>), or both (<a href="./references#CD006544-bbs2-0061" title="BrodszkyV , FarkasK , JaraiZ , LandiA , PecsvaradyZ , BajiP , et al. Effectiveness of prostanoids in patients with critical leg ischemia [Prosztanoidok hatasossaga kritikus vegtagischaemiaban.]. Orvosi Hetilap2011;152(51):2047‐55. [PUBMED: 22130202] ">Brodszky 2011</a>), for patients with critical limb ischaemia (CLI) who are unsuitable for rescue or reconstructive intervention. This updated systematic review analysed all studies included in those publications and identified additional studies; this contributed to a more comprehensive synthesis of the body of evidence on efficacy and safety of the whole family of prostanoids. </p> <p><a href="./references#CD006544-bbs2-0061" title="BrodszkyV , FarkasK , JaraiZ , LandiA , PecsvaradyZ , BajiP , et al. Effectiveness of prostanoids in patients with critical leg ischemia [Prosztanoidok hatasossaga kritikus vegtagischaemiaban.]. Orvosi Hetilap2011;152(51):2047‐55. [PUBMED: 22130202] ">Brodszky 2011</a> has highlighted that the previous version of this review pooled incorrect data for the rest‐pain relief outcome (<a href="./references#CD006544-bbs2-0105" title="RuffoloAJ , RomanoM , CiapponiA . Prostanoids for critical limb ischaemia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD006544.pub2] ">Ruffolo 2010</a>). For this update, we found considerable clinical heterogeneity regarding rest‐pain relief measurement across studies. Nevertheless, our criterion for pooling data was that the last measurement of rest‐pain assessment during the follow‐up period would be used as input, since this would be the most clinically relevant information for evaluating effects of prostanoids on this outcome beyond the immediate infusion period. </p> <p>A recent systematic review assessed the efficacy of prostanoids for patients with PAOD of any severity, with a treatment phase of at least 24 hours and a minimal follow‐up period of four weeks (<a href="./references#CD006544-bbs2-0103" title="VitaleV , MonamiM , MannucciE . Prostanoids in patients with peripheral arterial disease: a meta‐analysis of placebo‐controlled randomized clinical trials. Journal of Diabetes and Its Complications2016;30(1):161‐6. [PUBMED: 26516035] ">Vitale 2016</a>). Although the direction of results regarding amputation outcomes presented by <a href="./references#CD006544-bbs2-0103" title="VitaleV , MonamiM , MannucciE . Prostanoids in patients with peripheral arterial disease: a meta‐analysis of placebo‐controlled randomized clinical trials. Journal of Diabetes and Its Complications2016;30(1):161‐6. [PUBMED: 26516035] ">Vitale 2016</a> is consistent with that estimated by this update, differences in the ulcer healing pooled estimate could be explained by the fact that this update achieved greater statistical power by including additional studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006544-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram.*Out of 22 excluded studies, nine studies evaluated an inappropriate intervention for control group, seven included participants not fulfilling inclusion criteria with no available disaggregated outcome data, four were abstracts with no available full text, one had a quasi‐randomised design, and another was unpublished and had no available results." data-id="CD006544-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> <p>*Out of 22 excluded studies, nine studies evaluated an inappropriate intervention for control group, seven included participants not fulfilling inclusion criteria with no available disaggregated outcome data, four were abstracts with no available full text, one had a quasi‐randomised design, and another was unpublished and had no available results. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD006544-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006544-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Prostanoids versus placebo, outcome: 1.2 Total amputations." data-id="CD006544-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Prostanoids versus placebo, outcome: 1.2 Total amputations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Prostanoids versus placebo, outcome: 1.10 Total amputations. Sensitivity analysis excluding studies at high risk of attrition bias." data-id="CD006544-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Prostanoids versus placebo, outcome: 1.10 Total amputations. Sensitivity analysis excluding studies at high risk of attrition bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 1 Cardiovascular mortality." data-id="CD006544-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 1 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 2 Total amputations." data-id="CD006544-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 2 Total amputations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 3 Adverse events (participants)." data-id="CD006544-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 3 Adverse events (participants).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 4 Rest‐pain relief (dichotomous)." data-id="CD006544-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 4 Rest‐pain relief (dichotomous).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 5 Rest‐pain relief (dichotomous) ‐ sensitivity analysis." data-id="CD006544-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 5 Rest‐pain relief (dichotomous) ‐ sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 6 Rest‐pain relief (continuous)." data-id="CD006544-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 6 Rest‐pain relief (continuous).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 7 Reduction in analgesics consumption." data-id="CD006544-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 7 Reduction in analgesics consumption.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 8 Ulcer healing." data-id="CD006544-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 8 Ulcer healing.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 9 Ulcer healing ‐ sensitivity analysis." data-id="CD006544-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 9 Ulcer healing ‐ sensitivity analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 10 Major amputations." data-id="CD006544-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 10 Major amputations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 11 Minor amputations." data-id="CD006544-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 11 Minor amputations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prostanoids versus placebo, Outcome 12 All‐cause mortality." data-id="CD006544-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Prostanoids versus placebo, Outcome 12 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Prostanoids versus naftidrofuryl, Outcome 1 Total amputations." data-id="CD006544-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Prostanoids versus naftidrofuryl, Outcome 1 Total amputations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Prostanoids versus naftidrofuryl, Outcome 2 Adverse events (participants)." data-id="CD006544-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Prostanoids versus naftidrofuryl, Outcome 2 Adverse events (participants).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Prostanoids versus naftidrofuryl, Outcome 3 Rest‐pain relief." data-id="CD006544-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Prostanoids versus naftidrofuryl, Outcome 3 Rest‐pain relief.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Prostanoids versus naftidrofuryl, Outcome 4 Ulcer healing." data-id="CD006544-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Prostanoids versus naftidrofuryl, Outcome 4 Ulcer healing.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PGE1 versus ATP, Outcome 1 Total amputations." data-id="CD006544-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 PGE<sub>1</sub> versus ATP, Outcome 1 Total amputations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PGE1 versus ATP, Outcome 2 Adverse events (participants)." data-id="CD006544-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 PGE<sub>1</sub> versus ATP, Outcome 2 Adverse events (participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006544-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/urn:x-wiley:14651858:media:CD006544:CD006544-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_t/tCD006544-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Iloprost versus PGE1, Outcome 1 Adverse events (participants)." data-id="CD006544-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Iloprost versus PGE<sub>1</sub>, Outcome 1 Adverse events (participants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/media/CDSR/CD006544/image_n/nCD006544-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prostanoids compared with placebo for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Prostanoids compared with placebo for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> prostanoids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prostanoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality<br/> Follow‐up: range 2 months to 7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.41 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1170<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (13 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 1 month to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.86 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2825<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>269 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000<br/> (231 to 293) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 3 weeks to 7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.11<br/> (1.79 to 2.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>655<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>674 per 1000<br/> (572 to 798) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief (dichotomous)<br/> Follow‐up: range 1 month to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/> (1.06 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1179<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/> (241 to 362) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: range 3 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.24<br/> (1.04 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1719<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>358 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000<br/> (373 to 530) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because most studies were at high risk of bias (attrition bias).<br/> <sup>b</sup>Downgraded by one level for not meeting optimal information size (OIS) (for a 25% relative risk ratio (RRR), alpha = 0.05 and beta = 0.20, OIS = 13342). The 95% confidence interval includes both appreciable benefit and harm.<br/> <sup>c</sup>Even though eight trials were at high risk of attrition bias, a sensitivity analysis excluding those studies did not modify the effects of prostanoids (RR 0.91, 95% CI 0.75 to 1.10). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prostanoids compared with placebo for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prostanoids compared with pentoxifylline for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Prostanoids compared with pentoxifylline for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> prostanoids<br/> <b>Comparison:</b> pentoxifylline </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pentoxifylline</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prostanoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.50<br/> (0.05 to 5.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (3 to 301) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 1 month to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.24 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/> (69 to 420) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/> (0.72 to 2.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000<br/> (206 to 777) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.61<br/> (1.13 to 2.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>828 per 1000<br/> (581 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels owing to high risk of performance bias (open‐label study) and attrition bias, and owing to imbalance in baseline characteristics of participants with no mention of methods used for random sequence generation or allocation concealment.<br/> <sup>b</sup>Downgraded by one level owing to wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Prostanoids compared with pentoxifylline for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prostanoids compared with naftidrofuryl for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Prostanoids compared with naftidrofuryl for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> prostanoids<br/> <b>Comparison:</b> naftidrofuryl </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with naftidrofuryl</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with prostanoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 6 months to 4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.57 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>667 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>640 per 1000<br/> (380 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 3 days to 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.29<br/> (0.27 to 40.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/> (10 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: range 3 weeks to 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.07<br/> (0.83 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>605 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>648 per 1000<br/> (502 to 841) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: range 3 weeks to 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.46 to 2.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>39<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>416 per 1000<br/> (197 to 870) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of attrition bias.<br/> <sup>b</sup>Downgraded by one level owing to imprecision issues (low rate of events).<br/> <sup>c</sup>Downgraded by one level owing to high risk of bias (one trial presented high risk of performance and detection bias, and the other high risk of attrition bias).<br/> <sup>d</sup>Downgraded by one level owing to high risk of bias (most studies presented high risk of performance and detection bias or performance bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Prostanoids compared with naftidrofuryl for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PGE1 compared with ATP for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PGE<sub>1</sub> compared with ATP for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> PGE<sub>1</sub><br/> <b>Comparison:</b> ATP </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ATP</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PGE<sub>1</sub> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 3 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/> (0.09 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>91<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000<br/> (28 to 229) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event (participants)<br/> Follow‐up: range 3 weeks to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.78<br/> (1.41 to 5.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>91<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>530 per 1000<br/> (269 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rest‐pain relief</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported rest‐pain as a continuous outcome. Reanalysis was not possible.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing (complete)<br/> Follow‐up: median 3 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/> (0.17 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000<br/> (39 to 699) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> ATP: adenosine triphosphate; CI: confidence interval; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of attrition bias.<br/> <sup>b</sup>Downgraded by one level owing to a wide confidence interval resulting from a low rate of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PGE1 compared with ATP for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PGE1 compared with inositol niacinate for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>PGE<sub>1</sub> compared with inositol niacinate for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> PGE<sub>1</sub><br/> <b>Comparison:</b> inositol niacinate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inositol niacinate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PGE<sub>1</sub> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total amputations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events (participants)<br/> Follow‐up: range 2 weeks to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.60<br/> (0.79 to 3.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>65<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>533 per 1000<br/> (263 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: range 2 weeks to 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/> (0.88 to 2.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>725 per 1000<br/> (440 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Ulcer healing<br/> Follow‐up: range 2 weeks to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 3.06<br/> (0.41 to 22.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>65<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1000<br/> (23 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of attrition bias.<br/> <sup>b</sup>Downgraded by one level owing to a low rate of events resulting in wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">PGE1 compared with inositol niacinate for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Iloprost compared with PGE1 for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Iloprost compared with PGE<sub>1</sub> for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> iloprost<br/> <b>Comparison:</b> PGE<sub>1</sub> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PGE<sub>1</sub> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with iloprost</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Total amputations<br/> Follow‐up: range 4 weeks to 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.66 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>209<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>466 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000<br/> (308 to 564) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events (participants)<br/> Follow‐up: range 2 days to 4 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.35<br/> (1.82 to 3.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1000<br/> (368 to 615) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: range 21 days to 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/> (0.90 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>491 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>565 per 1000<br/> (442 to 722) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: range 21 days to 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.24<br/> (0.95 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>228<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1000<br/> (509 to 873) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to high risk of bias (performance, detection, and attrition bias).<br/> <sup>b</sup>Downgraded by one level owing to a low rate of events resulting in a wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Iloprost compared with PGE1 for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006544-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Clinprost compared with lipo‐PGE1 for critical limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Clinprost compared with lipo‐PGE<sub>1</sub> for critical limb ischaemia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> clinprost<br/> <b>Comparison:</b> lipo‐PGE<sub>1</sub> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with lipo‐PGE<sub>1</sub> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clinprost</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors mentioned the incidence of 1 death due to acute heart failure during the trial in the clinprost group. They did not discriminate whether this happened in the CLI from atherosclerotic origin group or in the thromboangiitis obliterans (TAO) group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total amputations</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> Follow‐up: median 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.83<br/> (0.56 to 5.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>135<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The trial authors did not discriminate whether adverse events happened in the CLI from atherosclerotic origin group or in the TAO group. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/> (32 to 346) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rest‐pain relief<br/> Follow‐up: median 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.58 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>67<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414 per 1000<br/> (228 to 737) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ulcer healing<br/> Follow‐up: median 28 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.74 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>457 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>539 per 1000<br/> (338 to 864) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; CLI: critical limb ischaemia; PG: prostaglandin; RCT: randomised controlled trial; RR: risk ratio; TAO: thromboangiitis obliterans. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level owing to few events, resulting in a wide confidence interval that includes both harms and benefits.<br/> <sup>b</sup>Downgraded by one level owing to high risk of bias (attrition rate &gt; 10%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Clinprost compared with lipo‐PGE1 for critical limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/full#CD006544-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006544-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Prostanoids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.41, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.35, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ciprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.25, 8.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total amputations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.86, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Taprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Lipo‐ecraprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.75, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Ciprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.68, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events (participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.79, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.76, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.49, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.68, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Rest‐pain relief (dichotomous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.06, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.07, 16.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.75, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.15, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Lipo‐ecraprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Rest‐pain relief (dichotomous) ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.88, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.75, 5.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.89, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Lipo‐ecraprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Rest‐pain relief (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.10, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.06, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [‐0.04, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Reduction in analgesics consumption <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.08, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.82, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.02, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Ulcer healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.04, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.81, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.13, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.09, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Ciprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.11, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Ulcer healing ‐ sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.83, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.13, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.99, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Major amputations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.61, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Taprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Lipo‐ecraprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.75, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Minor amputations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.11, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.07, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.75, 13.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Taprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.27, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.81, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.72, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.03, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Iloprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.60, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Taprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.52, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Lipo‐ecraprost</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.85, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Ciprostene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [0.49, 12.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Prostanoids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006544-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Prostanoids versus naftidrofuryl</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total amputations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [0.27, 40.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.73 [0.71, 194.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Rest‐pain relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.83, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 PGI2 (intravenous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 13.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 PGI2 (intra‐arterial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.80, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ulcer healing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.46, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PGE1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.34, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PGI2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.32, 7.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Prostanoids versus naftidrofuryl</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006544-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PGE1 versus ATP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total amputations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.09, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [1.41, 5.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PGE1 versus ATP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006544-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Iloprost versus PGE1 </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events (participants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.82, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Iloprost versus PGE1 </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006544.pub3/references#CD006544-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006544.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006544-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006544-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD006544-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006544-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006544-note-0014">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006544\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006544\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006544\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006544\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006544\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006544.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006544.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006544.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006544.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006544.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727496813"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006544.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727496817"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006544.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ead7efb44f573',t:'MTc0MDcyNzQ5Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 